MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
1 
  
     
DCP Protocol #:  MAY2016-07-01   
 
Local Protocol #:  MAY2016-07-01   
 
Phase II Trial of Weekly Erlotinib  Dosing to Reduce Duodenal Po lyp Burden Associated with 
Familial Adenomatous Polyposis 
  Consortium Name:   Cancer Prevention Network (CPN) Consortium Lead Investigator:   Paul J. Limburg, M.D., M.P.H. 
     P r o f e s s o r  o f  M e d i c i n e        M a y o  C l i n i c  C o l l e g e  o f  M e d i c i n e  
200 First Street, SW, Rochester, MN  55905 
     T e l e p h o n e :   5 0 7 - 284-2511 
     F a x :   507-266-4371 
     E - m a i l :   l i m b u r g . p a u l @ m a y o . e d u   
Organization Name:          Mayo Clinic in Arizona  
Protocol Principal Investigator:          N. Jewel Samadder, M.D., M.Sc.* 
            M a y o  C l i n i c  i n  A r i z o n a              13400 East Shea Boulevard 
            S c o t t s d a l e ,  A Z   85259 
            T e l e p h o n e :  480-301-8000 
            F a x :  480-301-7295 
            E - m a i l  a d d r e s s :  S a m a d d e r . j e w e l @ m a y o . e d u   Organization:           Mayo Clinic 
Statistician:            Nathan R. Foster, M.S.
 † 
            200 First Street SW, R ochester, MN  55905  
        Telephone: 507-284-5051         Fax:  507-266-4371         E-mail address: foster.nathan@mayo.edu 
 
* Investigator having NCI responsibility for this protocol   
† Study Contributor(s) not responsible for patient care 
 ClinicalTrials.gov:   [STUDY_ID_REMOVED] 
IND Sponsor:  NCI/Division of Cancer Prevention  
IND#:                                 64808  
Agent(s)/Supplier :   Erlotinib/NCI Division of Cancer Prevention   
NCI Contract #:   HHSN261201200042I 
Protocol Version Date:  July 22, 2019 Protocol Revision or   
Amendment #   Amendment 8 
 
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
2 
 Participating Investigators and Organizations  
Mayo Clinic in Arizona 
13400 East Shea Boulevard Scottsdale, AZ  85259 AZ020             
 
N. Jewel Samadder, M.D. 
Telephone: 480-301-8000; Fax: 480-301-7295 E-mail address: Samadder.jewel@mayo.edu  
University of Utah, Huntsman Cancer Institute 2000 Circle of Hope, Salt Lake City, UT 84112 UT003             
 
Priyanka Kanth, M.D. 
Phone: 801-581-7803; Fax: 801-585-5763 Email:Priyanka.kanth@hsc.utah.edu  Marta E. Heilbrun, M.D., M.S., Radiologist  
phone: (801) 581-2868 Email: marta.helbrun@hsc.utah.edu  
 
Michael Sossenheimer, M.D . 
Phone 801-581-7803; Fax 801-585-5763 
Michael.sossenheimer@hsc.utah.edu 
Mayo Clinic in Minnesota 200 First Street SW, Rochester, MN  55905 MN026 
 
Paul J. Limburg, M.D., M.P.H. Phone: 507-284-2511; Fax: 507-266-4371 Email: Limburg.paul@mayo.edu  Navtej Buttar, M.D. Phone: 507-284-2511; Fax: 507-266-4371 Email: buttar.navtej@mayo.edu 
 
Lisa Boardman, M.D. Phone:  507-284-2511; Fax:  507-266-4371 Email:  boardman.lisa@mayo.edu  
Cleveland Clinic 9500 Euclid Avenue, Cleveland, OH 44195 OH027 
 
Carol Burke, M.D. Phone: 216-444-6864; Fax: 216-444-6305 Email: burkec1@ccf.org  Gautam Mankany, M.D. Phone: 216-445-1249; Fax: 216-445-3889 Email: mankang@ccf.org  
University of Puerto Rico 
P.O. Box 70344, PMB 371 
San Juan PR 00927-8344 
PR008 
 Oncology Hospital Dr. Isaac Gonzalez 
Barrio Monacillos, Medical Center, Rio Piedras 
P.O. Box 191811 San Juan PR 00919-1811 PR021  
Marcia Cruz-Correa, M.D., Ph.D. 
Phone: 787-772-8300; Fax: 787-522-3282 Email: marcia.cruz1@upr.edu  Priscilla Magno Pagatzaurtundua, M.D. University of Puerto Rico 
Phone: 787-344-3775; Fax: 787-522-3282 
Email: Priscilla.magno@upr.edu   
 Victor L. Carlo, M.D. University of Puerto Rico 
Phone:  787-620-8716; Fax:  787-522-3282 
Email:  victor.carlo@upr.edu  Irene Villamil Sanchez, M.D. University of Puerto Rico 
Phone:  787-632-4575; Fax:  787-522-3292 
Email:  Irene.villamil1@upr.edu  
University of Michiga n, Medical School 
2150A Cancer Center, Ann Arbor, MI  48109 MI014 Danielle Turgeon, M.D. Phone:  734-764-6860; Fax:  734-936-7392 Email:  kturgeon@med.umich.edu  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
3 
 Elena M. Stoffel, M.D., M.P.H. 
Phone: 734-647-1417; Fax: 734-763-7672 
Email: estoffel@med.umich.edu  
MD Anderson Cancer Center 
1515 Holcombe Blvd.  Unit 1360 
Houston, TX 77030  
TX035  
Eduardo Vilar-Sanchez, M.D., Ph.D. 
Phone: 713-745-1836; Fax: 713-794-4403 Email: evilar@mdanderson.org  Patrick Lynch, J.D., M.D. Phone:  713-794-5073; Fax:  713-563-9740 Email:  plynch@mdanderson.org  Selvi Thirumurthi, M.D., M.S. 
Phone:  713-794-5073; Fax:  713-563-9740 
Email:  sthirumurthi@mdanderson.org  Margaret Dunseith, PA Phone:  713-745-1019; Fax: 713-563-9740 
Email: mmcguire2@mdanderson.org 
University of Pittsburgh Medical Center   
200 Lothrop Street, Pittsburgh, PA  15213 PA015  Rohit Das, M.D. 
Phone: 412-864-7091; Fax: 412-864-7080 
Email: dasr@upmc.edu  Robert Schoen, M.D., M.P.H. Phone: 412-648-7086; Fax: 412-648-7080 Email: rschoen@pitt.edu  
 
 
  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
4 
 Contacts 
Questions: Contact Name:  
Test schedule, Intervention 
Delays/Interruptions/Adjustments Adverse events Michelle Westover, CCRP, L ead Study Coordinator 
Huntsman Cancer Institute, University of Utah Phone:  801-581-4066     Fax: 801-585-5763 Email: michelle.westover@hci.utah.edu  
Serious Adverse Event reporting See Protocol Section 11.2 
Subject eligibility, Forms completion, paraffin-embedded specimens April Felt CPN  Research Base  Data Manager and Pathology Coordinator 
Phone: 507-538-0268    Fax: 507-266-3722 E-mail:  felt.april@mayo.edu 
CPN Lead Site Coordinator Colleen Akerley CPN Research Base  Senior Program Coordinator 
Phone: 507-284-2180     Fax: 507-266-4371 E-mail: akerley.colleen@mayo.edu  
Protocol Development Sharon Kaufman CPN Research Base Senior Research Protocol Specialist 
Phone: 507-293-1605     Fax: 507-266-4371 E-mail: kaufman.sharon@mayo.edu   
Regulatory 
Administrative Patty Simonson 
CPN Research Base Research Protocol Specialist 
Phone:  507-266-2218    Fax:  507-266-4371 E-mail:  Simonson.patricia1@mayo.edu   
Registration  CPN Registration Office ( 8:00-4:30 Cent ral Time) 
Phone: 507-284-4130; Fax: 507-284-0885 E-mail: random01@mayo.edu 
Monitoring Education Anne Holland CPN Research Base  Compliance Coordinator 
Email:  holland.anne@mayo.edu 
Phone : 507-293-7795 
All other biospecimens  BAP/Biospecimens collection, kits,  
and shipment Roxann Neumann, RN, BSN, CCRP 
CPN Research Base  Biospecimen Resource Manager 
Phone: 507-538-0602; E-mail:  Neumann.roxann@mayo.edu  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
5 
 SCHEMA 
 
Phase II Trial of Weekly Erlotinib  Dosing to Reduce Duodenal Po lyp Burden Associated with 
Familial Adenomatous Polyposis 
 
   
 
    
 
    
 
    
 
 
 
 
    
 
 
 
 
    
 
 Study Population 
• Familial Adenomatous Polyposis (Classic or Attenuated),  
• Duodenal polyposis, Spigelman stage 2-3 
• Females and males ≥ 18 years o f age and ≤69 years of age 
Informed Consent and P re-Registration (n=70) 
Screen 1 (n=70) 
• Physical exam, medical/surgical history 
• Alcohol and tobacco use assessments 
• Baseline symptoms, concomitant medications 
• Blood chemistry and hematology, pregnancy test (if applicable),  urinalysis 
• Research blood and urine collection 
Screen 2 (n=70) 
• Esophagogastroduodenoscopy (EGD)  and lower gastrointestinal (GI ) 
endoscopy 
• Biopsies and tattooing (See Section 7.3) 
Registration (n=60) 
Month 1 Visit (+/- 4 days) 
• Adverse events and concomitant medications assessment 
• Review of medication diary 
• Brief physical exam 
• Clinical blood tests and urinalysis Intervention (n=60) 
Erlotinib 350 mg/week x 6 months (without food) 
Monthly Telephone/Email Contact 
• Months 2, 4, 5 (+/- 7 days) 
• Adverse events and concomitant medications assessment 
• Review of medication diary 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
6 
  
 
Follow-Up Telephone/Email Contact at Month 7 (+/- 10 days)  
• Adverse events and concomitant medications assessment 
• Repeat blood tests if an y abnormal results at Month 6 
Primary Endpoints (n=50 evaluable) 
 
Polyp Burden:   To assess the mean percent change in duodenal p olyp burden 
(sum of diameters from all polyps) from baseline to 6 months po st-intervention 
for FAP subjects receiving weekly erlotinib.  The hypothesis is  that weekly 
erlotinib will significantly redu ce duodenal polyp burden after  6 months of 
treatment.   
 
Adverse events (if polyp burden shows a significant decrease fr om baseline):  To 
assess the grade 2/3 adverse event rate in this population and compare it to 
historical data.  The hypothesis is that weekly erlotinib will significantly reduce 
the grade 2/3 AE rate compared  to historical control data.  Month 3 (+/- 7 days) 
• Physical exam 
• Adverse events and concomitant medications assessment 
• Review of medication diary 
• Collect unused medication and dispense new supply 
• Clinical blood tests, urinalysis , research blood and urine coll ection 
• Pregnancy test, if applicable 
Post-Intervention Visit/Month 6 (+/- 10 days) (n=60) 
• Physical exam 
• Adverse events and concomitant medications assessment 
• Alcohol and tobacco use assessments 
• Collect unused medication and medication diary 
• Clinical blood tests, urinalysis , research blood and urine coll ection 
• EGD and lower GI endoscopy with biopsies 
• Pregnancy test, if applicable 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
7 
 TABLE OF CONTENTS     
 
Cover page .................................................... ................................................................................................ 1 
Investigators ................................................. ................................................................................................. 2 
Contacts ........................................................................................................................................................ 4 
Schema .......................................................................................................................................................... 5 
 1. Objectives 1.1 Primary objectives......................................... ............................................................... ......................... 10 
1.2 Secondary objectives ...................................... ............................................................... ....................... 10 
 2. Background 2.1 Familial Adenomatous Polyposis (FAP) ...................... ............................................................... ............ 10 
2.2 Erlotinib (Tarceva®) ...................................... ............................................................... .......................... 11 
2.3 Rationale ................................................. ............................................................... ............................... 12 
 3. Summary of Study Plan ...................................... ............................................................... ...................... 12 
 4. Participant Selection 
4.1 Pre-Registration Inclusion Criteria ....................... ............................................................... .................. 14 
4.2 Pre-Registration Exclusion Criteria ....................... ............................................................... ................. 14 
4.3 Registration Inclusion Criteria ........................... ............................................................... ..................... 15 
4.4 Registration Exclusion Criteria ........................... ............................................................... .................... 16 
4.5 Inclusion of Women and Minorities ......................... ............................................................... ............. 16 
4.6 Recruitment and Retention plan ............................ ............................................................... ............... 16 
 
5. Agent Administration 5.1 Dose regimen and dose groups .............................. ............................................................... ............... 17 
5.2 Erlotinib administration .................................. ............................................................... ....................... 17 
5.3 Run-in procedures ......................................... ............................................................... ......................... 17 
5.4 Contraindications ......................................... ............................................................... .......................... 17 
5.5 Concomitant medications ................................... ............................................................... ................... 17 
5.6 Dose modification ......................................... ............................................................... ......................... 18 
5.7 Adherence/compliance ...................................... ............................................................... .................... 20 
 6. Pharmaceutical Information 6.1 Erlotinib; IND# 64808; I ND Sponsor:  NCI, DCP ............. ............................................................... ......... 21 
6.2 Reported adverse events and potential risks ............... ............................................................... ......... 21 
6.3 Availa bility .............................................. ............................................................... ................................ 25 
6.4 Agent distribution ........................................ ............................................................... .......................... 25 
6.5 Agent accountability ...................................... ............................................................... ........................ 25 
6.6 Packaging and labeling .................................... ............................................................... ....................... 25 
6.7 Storage ................................................... ............................................................... ................................ 26 
6.8 Pre-Registration and Registration ......................... ............................................................... ................. 26 
6.9 Blindin
g and unblinding methods ........................... ............................................................... ............... 27 
6.10 Agent descript ion/disposal ............................... ............................................................... ................... 27 
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
8 
 7. Clinical evaluations and procedures 
7.1 Schedule of events ........................................ ............................................................... ......................... 28 
7.2 Baseline testing/Pr estudy evaluation ...................... ............................................................... .............. 30 
7.3 Evaluation during study intervention ...................... ............................................................... .............. 30 
7.4 Evaluation at completion of study intervention ............ ............................................................... ........ 31 
7.5 Post-interventio n follow-up period ........................ ............................................................... ............... 31 
7.6 Methods for clinical procedures ........................... ............................................................... ................. 31 
 8. Criteria for evaluation and endpoint definition 8.1 Primary endpoint .......................................... ............................................................... ......................... 33 
8.2 Secondary endpoints ....................................... ............................................................... ...................... 33 
8.3 Off-agent criteria ........................................ ............................................................... ............................ 34 
8.4 Off-study criteria ........................................ ............................................................... ............................ 34 
8.5 Study ter mination ......................................... ............................................................... ......................... 35 
 9. Correlative/special studies 9.1 Rationale for meth odology selection ....................... ............................................................... .............. 35 
9.2 Comparable methods ........................................ ............................................................... ..................... 35 
 
10. Specimen management 
10.1 Labora tories ............................................. ............................................................... ............................ 35 
10.2 Collection and handling procedures ....................... ............................................................... ............. 36 
10.3 Labeling and Shipping instructions ....................... ............................................................... ............... 39 
10.4 Tissue banking ........................................... ............................................................... ........................... 39 
 11. Reporting adverse events 11.1 Adverse events ........................................... ............................................................... .......................... 40 
11.2 Serious adve rse events ................................... ............................................................... ..................... 41 
 
12. Study monitoring 
12.1 Data management .......................................... ............................................................... ..................... 43 
12.2 Case rep ort forms ........................................ ............................................................... ........................ 43 
12.3 Source documents ......................................... ............................................................... ...................... 43 
12.4 Data and safety monitoring plan .......................... ............................................................... ............... 44 
12.5 Sponsor or F DA monitoring................................. ............................................................... ................. 44 
12.6 Record retention ......................................... ............................................................... ......................... 44 
12.7 CRADA/CTA ................................................ ............................................................... .......................... 44 
 13. Statistical considerations 
13.1 Study design/description ................................. ............................................................... .................... 44 
13.2 Randomization/stratification ............................. ............................................................... .................. 45 
13.3 Accrual and Feasibili
ty .................................. ............................................................... ....................... 45 
13.4 Primary objective, endpoint, analysis plan ............... ............................................................... ........... 46 
13.5 Secondary endpoints ...................................... ............................................................... ..................... 47 
13.6 Reporting and exclusions ................................. ............................................................... .................... 48 
13.7 Evaluation of toxicity.................................... ............................................................... ........................ 48 
13.8 Evaluation o f response ................................... ............................................................... ...................... 49 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
9 
 13.9 Interim Analysis ......................................... ............................................................... ........................... 49 
13.10 Ancillary studies ....................................... ............................................................... .......................... 49 
 
14. Ethical and regulatory considerations 14.1 FDA form 1572 ............................................ ............................................................... ......................... 50 
14.2 Other required documents ................................. ............................................................... ................. 50 
14.3 Institutional review board approval ...................... ............................................................... .............. 50 
14.4 Informed  consent ......................................... ............................................................... ........................ 50 
14.5 Submission of regulatory documents ....................... ............................................................... ........... 51 
14.6 Other .................................................... ............................................................... ................................ 51 
 15. Financing, expenses, and/or insurance ..................... ............................................................... ............. 52 
 References ................................................................................................................... ............................... 52 
 Summary of Changes – Informed Consent Form .................... ............................................................... ..... 54 
 Consent form template for consor tia cancer chemoprevention tria ls ....................................................... 55 
 
Appendices 
Appendix A. ECOG Per formance Status ........................... ............................................................... ............ 74 
Appendix B. Medication and Symptom Diary ...................... ............................................................... ........ 75 
Appendix C. Was It Worth I t (WIWI) Questionnaire .............. ............................................................... ...... 78 
Appendix D. Alcohol and Tobacco Use Assessments ............... ............................................................... .... 79 
Appendix E. Alcohol and Tobacco Use Cessation Resources ....... ...............................................................  86 
Appendix F. Diary of Medications  Used for Acid Reflux Symptoms ........................................................... 88 
   
  
  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
10 
 1. OBJECTIVES 
 
1.1 Primary Objectives   
 
• Polyp Burden:   To assess the mean  percent change in duodenal p olyp burden (sum of diameters 
from all polyps) from baseline to  6 months post-intervention for FAP subjects receiving weekly 
erlotinib.  The hypothesis is that weekly erlotinib will signif icantly reduce duodenal polyp burden 
after 6 months of treatment.   
• Adverse events (if polyp burden shows a significant decrease fr om baseline):  To assess the 
grade 2/3 adverse event rate in this population and compare it to historical data.  The 
hypothesis is that weekly erlotinib will significantly reduce t he grade 2/3 AE rate compared to 
historical control data.  
 
1.2 Secondary Objectives   
 
• To evaluate all adverse events  a t least possibly attributed to   weekly erlotinib; 
• To assess the absolute and percent  change in duodenal polyp num ber from baseline to 6 
months;   
• To assess the absolute and percent changes in lower gastrointes tinal polyp burden and number 
for the subset of participants w ith ileal pouch anal anastomosi s (IPAA) or ileo-rectal anastomosis 
with rectal stump (anticipated to be approximately 70% of regis tered cohort); and 
• To assess the absolute and percent change in desmoid tumor size  in participants who have 
baseline and follow up CTs performed as part of their standard of care (anticipated to be 
approximately 30% of the registered cohort); 
• Gene expression profiles in duodenal adenomas and uninvolved ti ssue will be compared 
between baseline and endpoint samples using negative binomial s tatistics (DESeq2): 
o Identify differentially expressed genes between duodenal polyps  and uninvolved tissue 
at endpoint compared to baseline; 
o Evaluate the effect of weekly erlotinib on EGFR and Wnt target gene expression in 
duodenal adenomas; 
o Evaluate the effect of weekly erlotinib on immune response sign aling in duodenal 
adenomas and uninvolved tissue. 
 
2. BACKGROUND 
 2.1 Familial Adenomatous Polyposis (FAP) 
 
Multiple studies have shown that the cyclooxygenase (COX) inhibitor, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), 
significantly inhibits colorectal adenomatous polyps 
in FAP patients.
1, 2 However, NSAIDs have 
demonstrated considerably less efficacy with respect to duodenal adenoma burden, based on a limited number of studies to date.
3, 4  Celecoxib use 
resulted in a modest reduction of duodenal5 and 
Figure 1. Effects of sulindac and erlotinib on 
signaling pathways, based on studies to date.  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
11 
 colorectal polyps,6, 7 but is no longer FDA-approved for this indication.8  Studies have suggested that APC 
inactivation and epidermal growth factor receptor (EGFR) signal ing promote COX-2 expression and the 
subsequent development of intestinal neoplasia.9, 10  Convergence between the Wnt and EGFR signaling 
pathways and COX-2 activity was demonstrated in a mouse model o f FAP, in which a combination of 
sulindac and an EGFR inhibitor diminished small intestinal aden oma development by 87%.11  Normally, 
APC down-regulates β−catenin through a complex with Axin, CK1, and GSK-3 β. Mutational inactivation 
of APC results in the accumulation and nuclear translocation of β−catenin where it interacts with TCF-
4/LEF-1 transcription factors to  activate genes whose products mediate proliferation, survival, and 
migration. Despite the fact that APC is mutated in the vast majority  of colorectal adenomas and 
adenocarcinomas in humans, caref ul examination of human colorec tal tumors in multiple studies have 
shown that nuclear β−catenin is found in only a small minority of microscopic and la rger adenomas, 
compared with approximately half  of adenocarcinomas. Thus, cons titutive activation of the canonical 
WNT signaling pathway appears to increase progressively during the adenoma-carcin oma sequence in 
the gut. However, the molecular events downstream of APC mutation at the early stages of neoplastic 
transformation are not entirely explained by the current model.   Prior studies from our group document 
that germline mutation of apc in zebrafish leads to a loss of r etinoid synthesis in colorecta l tissue early in 
the formation of polyps. This loss of retinoid expression is β−catenin-independent and results in the up-
regulation of cyclo-oxygenase 2 ( COX-2) in intestinal tissue (s ee Figure 1 ). COX-2 has been shown to 
drive the expression and release of growth factors, such as TGF α, and inflammatory mediators 
(prostaglandins, thromboxane, and prostacyclin), and, is a key target of chemopreve ntive agents.  An 
important target downstream of COX-2 is the epidermal growth fa ctor receptor (EGFR).  Preliminary and 
previous studies by Jones et al.  show that germline APC mutation alone is insufficient to cause nuclear 
localization of β−catenin and hence canonical WNT signaling in preneoplastic intestinal tissue and early 
adenomas.  Jones et al.  showed that co-activation of EGFR-RAS-MEK signaling is require d for the nuclear 
localization of β−catenin. Furthermore, EGFR activation increases COX-2 expressio n leading to 
reinforcement of EGFR activatio n and signaling. Progressive mut ational events, namely, loss of 
heterozygosity of APC and oncogenic activation of KRAS, further reinforce COX-2 and EGFR signaling 
crosstalk. 
 FAP patients are at greatly increased risk for duodenal neoplas ia, with duodenal adenomas eventually 
forming in >50% of FAP patients and duodenal adenocarcinoma occ urring in up to 12%.
12-17  In fact, 
following colectomy, duodenal aden ocarcinoma is the leading cau se of cancer death in FAP patients. 
Unfortunately, endoscopic and surg ical interventions are often challenging and suboptimal with respect 
to preventing invasive malignancy.18, 19  Therefore, it is imperative that more effective duodenal canc er 
prevention/control strategies be  developed for patients with FA P.  Building on positiv e findings from the 
recently completed FAPEST trial,  further definition of an effec tive, well-tolerated dosing regimen for 
erlotinib could favorably impact FAP standard of care with consequent improvements in morbidity, 
mortality, and quality of life.  
2.2 Erlotinib (Tarceva® NDA-021743) 
 
Erlotinib (Tarceva®, NDA-021743), an FDA-approved tyrosine kina se inhibitor, directly and reversibly 
inhibits the human EGFR tyrosine kinase with an IC 50 of 2 nM (0.79 ng/mL) in an in vitro enzyme assay 
and reduces EGFR autophosphorylation in intact tumor cells with  an IC 50 of 20 nM (7.9 ng/mL).  This 
potent inhibition is selective for the EGFR tyrosine kinase.  S tandard targeted therapy dosing ranges 
from 100-150 mg/day, based on pha rmacokinetic studies showing a n average plasma concentration of 
500ng/mL, which is targeted for clinical efficacy when treating  existing cancer.  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
12 
  
2.3 Rationale 
 
In our prior “Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients” trial (FAPEST; 
[STUDY_ID_REMOVED]), erlotinib at 75 mg/day was investigated and found  to be associated with marked 
duodenal neoplasia regression (fu rther described in section I) recently published in the Journal of the 
American Medical Association.20  However, agent tolerability was limited by acneiform rash and  oral 
mucositis. This resulted in dose  reductions, leading to FAPEST participants receiving an average erlotinib 
dose of 50 mg/day.  Another recent clinical trial in individuals with advanced premalignant head and 
neck lesions determined that erlotinib 50 mg/day was the maximu m tolerated dose with minimal 
observed toxicity yet retained histologic remission.21  Preclinical 22 and early phase clinical trial23, 24 data 
suggest that intermittent, once weekly dosing of erlotinib (sev en times the daily dose) yields clinical 
efficacy with fewer adverse effects, offering intriguing potent ial for chemopreventiv e application. Based 
on these findings, we propose t o evaluate the efficacy and tole rability of erlotin ib 350 mg/week as a 
candidate intervention for duodena l polyp regression in patient s with familial adenomatous polyposis 
(FAP). 
 Increasing evidence suggests tha t tobacco and alcohol use are risk factors in the development of 
intraepithelial neoplasia and cancer. In addition, tobacco and alcohol use may adversely affect agent 
intervention, for example by altering the safety profile or met abolism of a drug. Standardized 
assessments of tobacco and alcohol  use during clinical trials w ill aid in understanding the potential 
relationship between the use of these products and clinical end points or cancer prevention biomarkers. 
Therefore, NCI, DCP is including  assessment of tobacco and alco hol use at baselin e and Month 6, to 
determine the potential impact o f tobacco and alcohol use on 1)  treatment toxicity and symptom 
burden, and 2) the efficacy of treatment intervention.  
 
3. SUMMARY OF STUDY PLAN 
 General overview: We will evaluate the efficacy and toxicity of  a 6-month intervention of erlotinib 350 
mg/week in FAP patients (see Sc hema). Change in duodenal polyp burden (comparing post-intervention 
vs. baseline) will be assessed by esophagogastroduodenoscopy (EGD), utilizing field tested measurement protocols applied in our recently completed FAPEST study, and w ill serve as the p rimary endpoint.  
Adverse events will be monitored a nd reported according to NCI CTCAE v. 4.0 criteria.  The proposed 
trial will also provide a unique o pportunity to generate novel data regarding the RNA transcriptome in 
FAP patients, based on RNA sequencing (RNA-Seq) technology.  RN A-Seq will be performed on 
uninvolved duodenal mucosal biops y specimens obtained at the ba seline and post-intervention EGD 
exams (placed in RNA Later and st ored at -80°C prior to RNA iso lation).  These molecular studies will 
facilitate characterization of pa rticipant response at the cell ular level and will also offer new insights 
pertaining to the molecular mech anisms of duodenal polyp growth/regression.  Additional changes in 
duodenal and colorectal polyps w ill also be measured and compar ed between intervention arms as 
secondary endpoints.    Baseline Evaluation: Prior to r egistration, willing, consented participants will be screened in two stages, 
as outlined below. 
 
Screening 1: Individuals with FAP (classic or attenuated) will be identified from clinical practice and 
existing registries.  Willing, e ligible trial participants will  be consented (see Schema) and will undergo 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
13 
 physical exam; medical/surgical history; alcohol and tobacco us e assessment; blood chemistry and 
hematology testing; pregnancy test, if applicable; symptom and concomitant medica tion assessments; 
urinalysis, and research blood draw and urine collection. 
 Screening 2:  Esophagogastroduode noscopy (EGD) will be performe d to evaluate the duodenum using 
forward-viewing and/or side-viewing techniques (with still and video documentation). 
 
A tattoo will be placed 10 cm dis tal to the duode nal bulb to de fine a region heretofore referred to as the 
duodenal segment , which will extend from the duod enal bulb distally to point of  the tattoo. Endoscopic 
tattooing has been widely employe d in previous research protoco ls and is clinically advocated by many 
authorities.25, 26  For willing participants who are  undergoing lower endoscopy f or clinical purposes, 
rectal/pouch polyps may also be measured and recorded.  During the baseline endoscopy pr ocedures, one polyp will be sen t to the local pathology laboratory for 
histological analysis, since thi s assessment is a n inherent com ponent of the Spigelman stage 
categorization for duodenal po lyps.  Remaining polyps will be s ampled but not removed  (unless clinically 
required) from the 10 cm duodenal segment and rectum/pouch.  An y lesions containing high-grade 
dysplasia or cancer will result in study exclusion and will be managed with appropriate surgical or 
oncology referral(s).  All endosc opy exams will be recorded in high definition using Medicapture (or 
comparable) recorders to allow fo r blinded review as a future s econdary endpoint. 
 On Study:  60 eligible partici pants will be assigned to an inte rvention of erlotini b 350 mg once weekly 
without food. Study agents will be self-administered for a peri od of 6 months.  Participants will return 
for a visit at Month 1  (+/- 4 days) for brief physical exam, ad verse events assessment (especially 
weakness, fatigue, rash, diarrhe a, abdominal pain, melena, hema tochezia, nausea, vomiting), 
concomitant medications review, and blood and urine tests.  Participants will be contacted monthly (Months 2, 4, and 5) by the study coordinator to ensure medicat ion compliance and record adverse 
events. A diary of compliance an d symptoms will be maintained b y participants and reviewed during an 
office visit at 3 months (+/- 7 days).  The Month 3 study visit  will also include a physical exam, urinalysis, 
pregnancy test (if applicable), and blood draw for safety and t oxicity monitoring, as  well as research. 
Concomitant medications, adverse events, and medication complia nce will also be reviewed.  
Throughout the intervention period, participants will be provid ed with “adverse event medications” to 
counteract anticipated symptoms associated with the study agent s, based on observations from the 
FAPEST study. 
 
Post-Intervention:  At the Month 6 visit (+/- 10 days) or early  termination, participants undergo a 
physical exam, adverse event and concomitant medication assessm ents, laboratory studies, urinalysis, 
repeat pregnancy test (if applic able), follow up alcohol and to bacco use assessments, and research 
blood draw and urine collection.  EGD and lower GI endoscopy wi th biopsies will be performed 
according to the same protocols applied at baseline.  A follow up phone call will take place at month 7 
(+/- 10 days) to assess adverse events and repeat any blood tes ts that were outside of institutional limits 
of normal at Month 6. Any reported SAEs will be followed to res olution.  
  
 
  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
14 
 4. PARTICIPANT SELECTION 
 
4.1 Pre-Registration Inclusion Criteria 
 
4.1.1 Diagnosis of familial adenomatous polyposis (FAP) or atte nuated familial adenomatous 
               polyposis (AFAP), d efined as at least one of the  following: 
• Genetic diagnosis with confirmed  APC mutation (clinical CLIA ce rtified lab or research testing)  
• Obligate carrier  
• Clinical diagnosis of classic FA P with ≥ 100 colorectal adenoma s status post co lectomy and a 
family history of FAP  
• Clinical diagnosis of FAP, based  on personal and family history . Note:  This criterion requires 
documented review and agreement from either the Study Chair or the CPN Lead Investigator. 
 4.1.2  Age ≥18 and ≤69 years of age.  N ote: Because no dosing or adver se event (AE) data are 
               currently available on the use of erlotinib in p articipants <18 years of age, children are excluded 
               from this study but will be eligible for future pediatric trials, if applicable. 
 4.1.3     Ability to understand and the willingness to sign a written informed consent document 
 4.1.4     Willing to discontinue t aking NSAIDS for 30 days prio r to initiation of and during 
              intervention.  Exce ption: Use of ≤ 81 mg daily or  ≤ 650 mg weekly aspirin is allowed. 
 4.1.5    Willing to discontinue smoking for the duration of study intervention 
 4.1.6    Willing to provide manda tory biospecimens as specified  in the protocol 
 
4.2 Pre-Registration Exclusion Criteria 
 4.2.1   Any prior treatment with erlotinib or other agent whose  primary mechanism of action is known to 
            inhibit EGFR   
4.2.2   History of allergic rea ctions attributed to compounds o f similar chemical or biologic composition 
            to erlotinib 
 4.2.3   Use of potent CYP3A4 inhi bitors, including but not limi ted to ketoconazole, atazanavir,  
            clarithromycin, indinavir, itraconazole, nefazodone , nelfinavir, ritonavir, sa quinavir, telithromycin, 
            troleandomycin, voric onazole, and grapefruit or grapefruit juice 
 4.2.4   Use of potent CYP3A4 indu cers, including but not limite d to rifampicin, rifabutin, rifapentine, 
            phenytoin, carbamazepine, phenobarbital, and St. Jo hn's Wort 
 
4.2.5   Use of any other investigational agents ≤ 12 weeks prio r to pre-registration. 
 
4.2.6     Uncontrolled intercurre nt illness or recent surgical procedure that in the opinion of the  
              investigative team would limit compliance with st udy requirements, including, but not limited  
              to: 
• Ongoing or active infection  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
15 
 • Symptomatic congestive heart failure  
• Myocardial infarction ≤ 6 months prior to intervention  
• Severely impaired lung  function  
• Nonmalignant medical illnesses th at are uncontrolled or whose c ontrol may be jeopardized 
by the treatment with study intervention  
• Diagnosed liver disease, such as cirrhosis, chronic active hepa titis, or chronic persistent 
hepatitis  
• Unstable angina pectoris  
• Cardiac arrhythmia  
• Psychiatric illness/social situations  
 
4.2.7   History of invasive mali gnancy ≤ 3 years prior to pre-r egistration.  Exception:  adequately treated  
            carcinoma of the cervix, carcinoma in situ, or basa l or squamous cell carcinomas of the skin. 
 
4.2.8    Individuals on anticoagulation medications who cannot safely discontinue the medication for at 
             least 48 hours prio r to the study endoscopy, as de termined by the study investigator and/or 
             participant’s primary healthcare provider.  
 
4.2.9   History of any upper GI  s urgery that does not permit a ccess to or evaluation of a 10 cm segment  
            of the duodenum that includes the duodenal bulb, i. e. Whipple Procedure or similar 
 
4.3 Registration Inclusion Criteria 
 
4.3.1 ECOG performance status ≤1 (See Appendix A) 
 4.3.2 Adequate bone marrow and organ function:
 
 
• Leukocytes (WBC)  ≥ 3,000/uL (≥ 2,500/uL for African-American participants)  
• Platelet count ≥ 100 x 109/L 
• Hemoglobin ≥ 11.5 g/dL  
• Total bilirubin ≤ 1.5 x institut ional upper limit of normal (UL N) 
• Alkaline phosphatase ≤ 1.5 x insti tutional upper limit of norma l (ULN) 
• AST/SGOT ≤ 2 x institutional upper limit of normal (ULN) 
• ALT/SGPT ≤ 2 x institutional upper limit of normal (ULN)  
• Creatinine ≤ institutional upper limit of normal (ULN)  
• Urinary testing results within institutional limits of normal o r deemed clinically insignificant.  
 4.3.3  Spigelman 2-3  4.3.4 Not pregnant or breast feeding.  Note:  The effects of er lotinib (Tarceva ®) on the developing 
               human fetus at the recommended therapeutic dose are unknown. For this reason, women of 
               child-bearing potential and men must agree to us e adequate contraception (hormonal or  
               barrier method of birth control; abstinence) pri or to study entry and for the duration of study 
               participation. Should a woman become pregnant or  suspect she is pregnant while participating 
               in this study, she should inform her study physi cian immediately. Breastfeeding should be 
              discontinued if the mother is treated with erloti nib. 
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
16 
 4.3.5   Willing to use adequate contraception to avoid pregnancy or impregnation until 2 weeks 
            after discontinuing study agent  
4.4   Registration Exclusion Criteria  
 
4.4.1   Histologically-confirmed  high grade dysplasia (HGD), ca ncer, or polyp burden that is not 
            quantifiable. 
 
4.4.2   Regular (≥ 2 times per w eek) use of drugs that alter th e pH of the GI tract, such as proton pump 
            inhibitors (PPI) and antacids.  Exceptions:  Indivi duals who use prescription PPIs and have 
            approval from their primary health care provider to  replace the PPI with an H2 receptor agonist, 
            i.e. ranitidine, for the duration of the trial will  be eligible. See Section 5.5 for details.  
 
4.4.3   Gastrointestinal bleeding.  Note that the presence of a ny symptoms (dyspnea, fatigue, angina, 
            weakness, malaise, melena, hematochezia, hematemesi s, anemia, abdominal pain) will require 
            clinical assessment to rule out gastrointestinal bl eeding.  
 
4.5 Inclusion of Women and Minorities  
 
Both men and women and members o f all races and ethnic groups are eligible for this trial.  Participants 
may be English-speaking or non-E nglish-speaking. The Participat ing Organizations (POs) were chosen, in 
part, based on access to the tar get participant population and access to potential participants of diverse 
backgrounds.  Refer to each PO’s  Recruitment, Retention, and Ad herence (RR&A) Plan for details.  
 
4.6 Recruitment and Retention Plan 
 Each Participating Organization  will be required to develop and  submit a study- and site-specific RR&A 
plan for the purposes of insuring equal access to the clinical trial by individuals of all genders, races, and 
ethnic groups and for attaining the organization’s accrual targ et.  POs will use the RR&A Plan Worksheet 
as the basis for their plans.  Each PO will be asked to provide  a monthly accrual target.  The CPN 
Operations team will monitor progress toward that target and request revised/corrective RR&A plans if necessary, RR&A plans will be revi ewed quarterly, at a minimum,  in accordance with a master accrual 
target plan developed cooperativ ely between the CPN and DCP tea ms. 
 
In general, site study teams will be identified by the site PI.   With assistance from the CPN Operations 
Office, training in study implementation and roles in the RR&A plan will be provided by the site PI or 
designee.  Potential participants will be identified by site st udy teams by review of existing hereditary 
gastrointestinal cancer registries, clinical referral, family e xpansion, and self-referral.  In all cases, only 
individuals who have consented to being contacted for future re search will be contacted regarding this 
clinical trial. The trial will be  posted on clinicaltrials.gov and, if applicable, each  of the institutions’ 
clinical trial web sites.  Participant consent, screening, and study visits will be imp lemented per protocol 
and per institutional policies  and procedures. Study teams will maintain contact participants per 
protocol to improve compliance,  retention, and adherence. 
   
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
17 
 5. AGENT ADMINISTRATION 
 
Intervention will be administered on an outpatient basis. Repor ted AEs and potential risks are described 
in Section 6.2.  
 
5.1 Dose Regimen and Dose Groups 
 Erlotinib (Tarceva
®), 350 mg once per week for 6 months.  
 
5.2 Erlotinib  Administration  
 
• Participants will be dispensed erl otinib at the time of Registration and at the Month 3 visit.  
• At each time point, participants will be dispensed 30 tablets o f erlotinib 150 mg and 30 tablets 
of erlotinib 25 mg.   
• Participants will self-administe r one weekly dose consisting of two 150 mg tablets and two 25 
mg tablets.  If a dose reduction is indicated (see Section 5.6) , the participant will take one 150 
mg tablet and one 25 mg erlotinib tablet.  
• Erlotinib will be taken with 200 mL of water on the same day and approximately the same time 
each week.  This will be done at l east one hour before or two h ours after any food intake. 
 
5.3 Run-in Procedures   
 
There will be no run in procedures. 
 
5.4 Contraindications 
 
• Smoking (Urine cotinine testing will be done pre- and post-intervention to monitor exposure to 
smoke)  
• Medications that alter the pH of the upper GI tract, such as PP Is and antacids  
 
5.5 Concomitant Medications 
 Patients who are being concomitantly treated with potent CYP3A4  inducers will not be eligible for this 
study.  Potent CYP3A4 inhibitors include, but are not limited t o ketoconazole, atazan avir, clarithromycin, 
indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saq uinavir, telithromycin, troleandomycin, 
voriconazole, and grapefruit or grapefruit juice.  Potent CYP3A 4 inducers include but are not limited to 
rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, p henobarbital, and St. John's Wort. 
 Drugs that alter the pH of the upper GI tract may alter the sol ubility of erlotinib and reduce its 
bioavailability.  Coadministration of erlotinib with omeprazole , a proton pump inhibitor (PPI), decreased 
the erlotinib exposure and maximu m concentration by 46% and 61% , respectively; therefore, the 
concomitant use of proton pump in hibitors with erlotinib should  be avoided.  Individuals who take 
prescription PPIs at the time of registration, who, in the clin ical judgement of the in vestigator, can safely 
transition off the PPI to an H2 re ceptor agonist (i.e. ranitidi ne), and can tolerate not taking the H2 
blocker on the day before and the day of erlotinib dosing can b e eligible. 
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
18 
 Altered coagulation parameters and infrequent reports of bleedi ng events, including gastrointestinal 
and non-gastrointestinal bleedin g, have been reported in patien ts in erlotinib clin ical studies, some 
associated with concomitant warf arin administration. Patients t aking anticoagulants will be excluded 
from study participation if, in the opinion of the study invest igator and/or primary health care provider, 
they cannot safely discontinue t he medications for at least 48 hours prior to the endoscopy procedures.   
 
Patient must discontinue taking any NSAIDS (including sulindac) within thirty days ( 30 days) of treatment 
initiation. However, patients using 81 mg daily aspirin or 650 mg aspirin not more than once a week are 
eligible.   
All medications (prescription and over-the-counter), vitamin and mineral supplements, and/or herbs 
taken by the participant will be d ocumented on the concomitant medication CRF and will include: 1) 
start and stop date, dose and ro ute of administration, and indi cation. Medications taken for a procedure 
(e.g., biopsy) should also be included. 
 
5.6 Dose Modification 
 This study will utilize the CTCA E (NCI Common Terminology Crite ria for Adverse Events) Version 4.0 for 
toxicity and Serious Adverse Event reporting.  A copy of the CTCAE can be found at 
http://ctep.cancer.gov/protocolDevelopment/electronic_applicati ons/ctc.htm  
 
Dose reduction or interruption o f erlotinib for toxicity may ta ke place at any time during the study at the 
discretion of the investigator.  Toxicity grading is based on NCI-CTCAE, v 4.0.  Dose level reductions are 
presented in Table 1 .  If participants do not tolera te the second erlotinib dose re duction, treatment is to 
be discontinued.  
 
Table 1 
Dose Level Reductions 
Drug Starting Dose  First Reduction Second Reduction 
Erlotinib 350 mg  
once per week 175 mg  
once per week 0 mg/week 
(intervention 
holiday) 
 Erlotinib specific toxicities: Dose reductions may be implemented at the discretion of the inv estigator.  At the discretion of the 
treating physician and when it is in the best interests of the study participant, a dose holiday can be 
implemented even prior to a dose reduction.  Recommendations fo r dose reductions due to adverse 
events are as follows:  All study participants will be adv ised to use loperamide or com parable medication at the earliest onset 
of diarrhea.  All study participa nts will be provided with pres criptions for alcohol-free emollient cream, 
oral antibiotics (tetracycline, minocycline, or doxycycline), t opical clindamycin, diphenhydramine, topical 
or oral corticosteroids at discr etion of investigator. These ar e to be used as needed to manage expected 
symptoms.  It is estimated that approximately 30% of participan ts may require eye  drops or stronger 
antibiotics for symptom management.   
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
19 
 Management of a tolerable Grade 2 or 3 rash should include continuation of erlotinib at the current 
dose and symptomatic management.   If skin rash is intolerable, dose reduction according to Table 2 
should be considered.  When skin  toxicity improves by at least one grade level, the dose may be 
re-escalated as tolerated.  In Phase II trials, this approach e nabled dose re-escalation for the majority of 
participants requiring dose redu ction for skin t oxicity.  Parti cipants experiencing Grade 4 skin toxicity 
should be discontinued from study treatment.      A detailed flow diagram for management of erlotinib-related ras h is available on the CPN website at this 
location: https://cancerpr.ipower.com /member/MAY2016-07-01.shtml    See Protocol Section 8.3 for 
information regarding follow-up ac tivities for participants who , due to adverse events, must discontinue 
study agent before study completion.  For Grade 1 or 2 diarrheas, early intervention should include c ontinuation of erlotinib at the current 
dose and initiation of loperamide therapy as described in Table 2.  Grade 2 diarrhea that persists over 
48–72 hours, despite optimal medical management, should be mana ged by dose reduction according to 
Table 2 .  Participants experiencing Grade 3 diarrhea should interrupt erlotinib until resolution to Grade 
≤1 and re-start at a reduced dose according to Table 2 .  Participants should be maintained at the 
reduced dose without attempt at d ose re-escalation.  Participan ts experiencing Grade 4 diarrhea should 
be discontinued from study treatment.  Erlotinib should not be restarted in those suspected of having drug-related interstitial lung disease (ILD). 
For any participants being taken off study due to a SAE, the is sue will be reported as described in Section 
11.2.   
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
20 
 Table 2.  Dosage Modification Criteria and Guidelines for Manag ement  
of Erlotinib -Related Toxicities 
NCI-CTCAE  
(v 4.0) Grade Erlotinib Dose Modification Guideline for Management 
Diarrhea 
Grade 1 None Consider loperamide (4 mg at first onset, 
followed by 2 mg q 2–4 hours until free 
of diarrhea for 12 hours) 
Grade 2 None 
(Dose reduction of erl otinib is necessary if 
diarrhea persists over 48–72 hours despite optimal medical management) Loperamide (4 mg at first onset, followed by 2 mg q 2–4 hours until diarrhea free for 12 hours) 
Grade  3 Interrupt then dose reduce erlotinib. 
Erlotinib should not be re-escalated. Interrupt erlotinib until resolution to 
Grade ≤1, and restart at next reduced 
dose 
Grade 4 Discontinue study treatment.  
Pulmonary Events (if possibly ILD) 
All Grades Temporarily inte rrupt erlotinib pending the 
diagnostic evaluation.  If the pulmonary 
adverse event is assessed as related to erlotinib, discontinue the participant from study treatment. Unexplained dyspnea, either new or progressive, should be aggressively evaluated.   
Rash 
Grade 1 and 2 and 
Tolerable rash None Any of the following: alcohol-free 
emollient cream, oral antibiotics (tetracycline, minocycline, doxycycline) 
topical clindamycin, diphenhydramine, topical or oral corticosteroids at discretion of investigator 
Grade 3 or Intolerable rash Consider interruption and or dose reduction if unresponsive to symptomatic management.  Re-escalation is allowed. Manage as described above 
Grade 4 Discontinue study treatment. Manage as described above 
 
 
5.7 Adherence/Compliance 
 5.7.1 Participant compliance with  study visit and requirements will be documented.  Compliance with 
taking study medications will be d ocumented via the use of medi cation diaries and recorded on case 
report forms for appropriate su bgroup statistical analysis.  
 5.7.2 Participants will be required to complete and submit medi cation diaries.  Dispensed and 
returned medication will be accou nted for according to DCP and Participating Organization policies and 
procedures.  
 
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
21 
  
6. PHARMACEUTICAL INFORMATION 
 
6.1 Erlotinib (IND#: 64808,  IND Sponsor: NCI, DCP)   
 
Clinical studies investigating th e chemopreventive efficacy of erlotinib are conducted under IND 64808 
sponsored by NCI, DCP. Erlotinib (Tarceva®) is an epidermal growth facto r receptor (EGFR) inhibitor 
approved by the FDA as a targete d therapy for the treatment of patients with locally advanced or 
metastatic non-small ce ll lung cancer (NSCLC) whose tumors have EGFR e xon 19 deletion or exon 21 
(L8568R) substitution mutation, after failure of at least one prior chemotherapy regimen. It is  also 
indicated as first-line therapy for treatment of patients with locally advanced, unresectable, or 
metastatic pancreatic cancer in combination with gemcitabine. 
 
Erlotinib drug product is manufactured for OSI Pharmaceuticals,  LLC by Astellas Pharma US (Northbrook, 
IL; Astellas). Erlotinib is currently formulated as conventiona l, immediate-release tablets in 25 mg, 100 
mg, and 150 mg strengths. For th e purpose of this study, 25 and  150 mg strength tablets will be used. 
Erlotinib drug substance is an off-white to pale yellow powder.  Conventional excipients in the 
formulation include lactose mono hydrate, hypromellose, hydroxyp ropyl cellulose, microcrystalline 
cellulose, sodium starch glycolat e, sodium lauryl sulfate, magn esium stearate, and titanium dioxide.  
 
6.2 Reported Adverse Events and Potential Risks 
 
Safety evaluation of erlotinib is based on more than 1200 cancer patients who received erlotinib as a 
targeted therapy, more than 300 patients who received 100 or 15 0 mg erlotinib plus gemcitabine, and 
1228 patients who received erlotinib concurrently with other ca ncer treatments. The most common 
adverse reactions with erlotinib  are rash and diarrhea usually with onset during the first month of 
treatment. The incidences of rash and diarrhea from clinical st udies of erlotinib for the treatment of 
NSCLC and pancreatic cancer were 70% for rash and 42% for diarrhea.   
In first-line treatment of NSCLC patients with EGFR mutations, the most frequent (≥30%) adverse 
reactions in erlotinib-treated p atients were diarrhea, asthenia , rash, cough, dyspnea, and decreased 
appetite.  Adverse events occurri ng in 4–20% of erlotinib-treat ed patients included p ruritus, dry skin, 
and paronychia. The median time to onset of rash was 15 days an d the median time to onset of diarrhea 
was 32 days. The most frequent grade 3/4 adverse reactions were rash and diarrhea. Dose interruptions or reductions due to adverse reac tions occurred in 37% of erlot inib-treated patients, and 14.3% of 
erlotinib-treated patients disco ntinued therapy due to adverse reactions. In erlotinib-treated patients, 
the most frequently reported adv erse reactions leading to dose modification were rash (13%), diarrhea 
(10%), and asthenia (3.6%). One erlotinib-treated patient exper ienced fatal hepatic failure and four 
additional patients experienced grade 3/4 liver test abnormalit ies in the first-line, randomized, open-
label clinical trial o f erlotinib in NSCLC. 
 
As maintenance treatment in patients with locally advanced or m etastatic NSCLC whose disease did not 
progress during first-line platinum-based chemotherapy, the mos t common adverse reactions in 
patients receiving single-agent 150 mg erlotinib were rash and diarrhea. Grade 3/4 rash and diarrhea 
occurred in 9% and 2%, respectively, in erlotinib-treated patie nts. Rash and diarrhea resulted in study 
discontinuation in 1% and 0.5% of erlotinib-treated patients, r espectively, and d ose reduction or 
interruption for rash and diarrh ea was needed in 5% and 3% of p atients, respectively. In erlotinib-
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
22 
 treated patients the median time to onset of rash was 10 days, and the median time to onset of diarrhea 
was 15 days. Liver test abnorma lities including alanine aminotransferase (ALT) elevations were observed 
at grade 2 or greater severity i n 3% of erlotinib-treated patie nts and 1% of placebo-treated patients. 
Grade 2 and above bilirubin elevat ions were observed in 5% of e rlotinib-treated patients and in <1% in 
the placebo group. 
 
In a study comparing first-line maintenance therapy with erloti nib administered at the time of disease 
progression in late-stage NSCLC, 11 deaths due t o AEs occurred in patients who received erlotinib 
(pulmonary embolism [3 patients], pneumonia [2 patients], cardi o-respiratory arrest, cardio-pulmonary 
failure, metabolic acidosis, cer ebrovascular accident, hemoptys is, aspiration pneumonia) compared with 
3 patients who received placebo (lobar pneumonia, hydrocephalus , respiratory failure). 
 In a study of erlotinib in second- and third-line treatment of NSCLC, the most commo n adverse reactions 
were also rash and diarrhea. Grade 3/4 rash and diarrhea occurr ed in 9% and 6%, respectively, in 
erlotinib-treated patients. Rash  and diarrhea each resulted in study discontinuation in 1% of erlotinib–
treated patients, and 6% percent and 1% of patients needed dose  reduction for rash and diarrhea, 
respectively. The median time to onset of rash was 8 days, and the median time to onset of diarrhea was 12 days. Liver function test abnormalities (including eleva ted ALT, aspartate aminotransferase 
[AST], and bilirubin) were observed in patients receiving singl e-agent erlotinib at 150 mg. These 
elevations were mainly transient  or associated with liver metas tases. Grade 2 (>2.5–5.0 × ULN) ALT 
elevations occurred in 4% and <1 % of erlotinib and placebo trea ted patients, respectively. Grade 3 
(>5.0–20.0 × ULN) elevations were not observed in erlotinib-tre ated patients. 
 The most common AEs in pancreatic cancer patients receiving 100  mg erlotinib plus gemcitabine were 
fatigue, rash, nausea, anorexi a, and diarrhea; less common AEs included weight loss. In the 
erlotinib/gemcitabine arm, grade  3/4 rash and diarrhea were eac h reported in 5% of patients. The 
median time to onset of rash a nd diarrhea was 10 days and 15 da ys, respectively. Rash and diarrhea 
each resulted in dose reductions  in 2% of patients and resulted  in study discontinuation in up to 1% of 
patients receiving erlotinib/gemcitabine. T he 150 mg cohort was  associated with a higher rate of certain 
class-specific AEs, including rash, and required more frequent dose reduction or interruption. 
 In the pancreatic carcinoma tria l, 10 patients in the erlotinib /gemcitabine group developed deep venous 
thrombosis (incidence 3.9%), compared with three patients in th e placebo/gemcitabine group (incidence 
1.2%). The overall incidence of g rade 3 or 4 thrombotic events,  including deep venous thrombosis, was 
similar in the two treatment arm s: 11% for erlotinib/gemcitabin e vs. 9% for placebo/gemcitabine. Liver 
function test abnormalities (including elevated ALT, AST, and b ilirubin) were also observed. The 
erlotinib/gemcitabine treatment group had grade 2 (>2.5–5.0 × U LN) ALT elevations in 31% and grade 3 
(>5.0–20.0 × ULN) elevations in 13% compared with 22% for grade  2 and 9% for grade 3 in the 
placebo/gemcitabine group.  
 
There have been infrequent reports of serious interstitial lung  disease (ILD)-like events, including 
fatalities, in
 patients receiving erlotinib for treatment of NS CLC, pancreatic cancer, or other advanced 
solid tumors. In the randomized s ingle-agent NSCLC study the in cidence of ILD-like events was the same 
in both the placebo and erlotini b groups (0.8%). In the pancreatic cancer study (in combination with 
gemcitabine), the incidence of I LD-like events was 2.5% in the erlotinib/gemcitabine group vs. 0.4% in 
the placebo/gemcitabine group. T he overall incidence of ILD-lik e events in approximately 32,000 
erlotinib-treated patients from all studies (including uncontro lled studies and studies with concurrent 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
23 
 chemotherapy) was approximately 1.1%. Reported diagnoses in patients suspected of having ILD-like 
events included pneumonitis, radiation pneumonitis, hypersensit ivity pneumonitis, interstitial 
pneumonia, interstitial lung disea se, obliterative bronchioliti s, pulmonary fibrosis, acute respiratory 
distress syndrome, and lung infil tration. Symptoms started from  five days to more than nine months 
(median 39 days) after initiating erlotinib therapy. In the lun g cancer trials, most of the cases were 
associated with confounding or con tributing factors such as con comitant/prior chemotherapy, prior 
radiotherapy, pre-existing parenchymal lung disease, metastatic  lung disease, or pulmonary infections. 
 
Cases of hepatorenal syndrome, acute renal failure (including fatalities), or renal insufficiency with or without hypokalemia have been reported. Some were secondary to severe dehydration due to diarrhea, 
vomiting, and/or anorexia while others were confounded by concurrent chemotherapy use.   Asymptomatic increases in liver  transaminases have been observe d in erlotinib-treated patients. Rare 
cases of hepatic failure (including fatalities) have been repor ted during postmarketing use of erlotinib. 
Confounding factors for severe hepatic dysfunction have include d pre-existing liver disease or 
concomitant treatment with potentially hepatotoxic drugs. The p ooled incidence of hepatic failure in the 
three monotherapy lung cancer studies, where patients with mode rate to severe hepatic impairment 
were excluded, was 0.4% in the erlotinib arms and 0% in the con trol arms. The incidence of hepatic 
failure in the pancreatic cancer study was 0.4% in the erlotini b plus gemcitabine arm and 0.4% in the 
control arm.  During NSCLC and combination pancreatic cancer trials, infreque nt cases of gastrointestinal bleeding 
have been reported, some associat ed with concomitant warfarin o r NSAID administration. These AEs 
were reported as peptic ulcer bl eeding (gastritis, gastroduodenal ulcers), hematemesis, hematochezia, 
melena, and hemorrhage from possible colitis. Gastrointestinal perforation, including fatal cases, have 
been rarely reported with erloti nib treatment. Patients receivi ng concomitant anti-angiogenic agents, 
corticosteroids, NSAIDs, or taxane-based chemotherapy, or who h ave prior history of peptic ulceration 
or diverticular disease may be a t increased risk of perforation. The pooled incidence of gastrointestinal 
perforation in the three monothe rapy lung cancer studies was 0. 2% in the erlotinib arms and 0.1% in the 
control arms. The incidence of g astrointestinal perforation in the pancreatic cancer study was 0.4% in 
the erlotinib plus gemcitabine a rm and 0% in the control arm. 
 Corneal ulcerations or perforations have been reported in patie nts receiving erlotinib. Decreased tear 
production, abnormal eyelash gro wth, keratoconjunctivitis sicca , and keratitis have been reported and 
are risk factors for corneal ulc eration/perforation.   Hair and nail changes, mostly non-serious, were 
reported; paronychia was reporte d commonly and hirsutism, eyela sh/eyebrow changes, and brittle and 
loose nails were reported uncom monly.  Bullous, blistering, and  exfoliative skin conditions, including 
cases suggestive of Stevens-Johnson syndrome/toxic epidermal ne crolysis, which in some cases were 
fatal, can occur with erlotinib treatment. The p ooled incidence of bullous and exfoliative skin disorders 
in the three monotherapy lung cancer studies was 1.2% in the er lotinib arms and 0% in the control arms. 
The incidence of bullous and exfo liative skin disorders in the pancreatic cancer study was 0.4% in the 
erlotinib plus gemcitabine arm and 0% in the control arm.  In the pancreatic carcinoma tria l, six patients (incidence 2.1% ) in the erlotinib/gemcitabine group 
developed myocardial infarction/ischemia. One of these patients  died due to myocardial infarction. In 
comparison, three patients in the placebo/gemcitabine group dev eloped myocardial infarcti
 on 
(incidence 1.1%) and one died due  to myocardial infarction. In the same trial, seven patients in the 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
24 
 erlotinib/gemcitabine group deve loped cerebrovascular accidents  (incidence 2.5%). One of these was 
hemorrhagic and was the only fatal event. In contrast, there we re no cerebrovascular accidents in the 
placebo/gemcitabine group. The pooled incidence of microangiopa thic hemolytic anemia with 
thrombocytopenia in the three mo notherapy lung cancer studies was 0% in the erlotinib arms and 0.1% 
in the control arms. The incidence of microangiopathic hemolyti c anemia with thrombocytopenia in the 
pancreatic cancer study was 1.4% in the erlotinib plus gemcitab ine arm and 0% in the control arm. Other 
mild skin reactions, such as hyperpigmentation, have been obser ved uncommonly (in <1% of patients). 
 
In the previously reported FAPEST study, 83% of participants ex perienced Grades 1-3 adverse events. 
There were no Grade 4 or 5 event s. The most common adverse even t was an erlotinib-induced 
acneiform-like rash, which occurred in 87% of the treatment gro up (n=40) and 20% of the placebo group 
(n=9) ( P < .001). The rash was managed with topical cortisone and/or clindamycin therapy. Additional 
adverse events commonly increase d in the treatment group includ ed oral mucositis (39.1%; n=18), 
diarrhea (26%; n=12), and nausea (23.9%; n=11).  Of the partici pants who completed the study, 73% had 
erlotinib dose reductions due to grade 1 and 2 rash that were d eemed intolerable by the participants.20 
 Erlotinib can cause fetal harm w hen administered to a pregnant woman; therefore, women should avoid 
becoming pregnant while being tre ated with erlotinib. Adequate contraceptive methods should be used 
during therapy and for at least two weeks after discontinuing e rlotinib. There are no adequate and well-
controlled studies in pregnant women using erlotinib; however, studies in animals have shown some 
reproductive toxicity. Breastfeeding  should be discontinued while takin g erlotinib. While it is not known 
whether erlotinib is excreted in  human milk, erlotinib and/or i ts metabolites were excreted in milk in 
animals.   
Erlotinib is protein bound (92–95%) in humans and metabolized i n the liver by c ytochrome P450 
(CYP)3A4, and to a lesser extent CYP1A2, and in the lungs by CYP1A1. A potential for drug-drug 
interaction exists when erlotinib is coadministered with drugs that are highly protein bound or that are 
potent CYP3A4 inhibitors/inducers . Potent inducers of CYP3A4 ac tivity increase erlotinib metabolism 
and significantly decrease erlotinib plasma concentrations, whi le potent CYP3A4 inhibitors increase 
exposure to erlotinib. For patients who are being concomitantly  treated with a potent CYP3A4 inhibitor, 
a dose reduction should be considered in the presence of severe  AEs. For patients who are being 
concomitantly treated with a potent CYP3A4 inducer, alternative  treatments that l ack potent CYP3A4-
inducing properties should be considered. Potent CYP3A4 inhibit ors include ketoconazole, atazanavir, 
clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir , ritonavir, saquinavir, telithromycin, 
troleandomycin, voriconazole, and grapefruit or grapefruit juic e. CYP3A4 inducers include rifampicin, 
rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital , and St. John's Wort. 
 
Cigarette smoking has been shown  to reduce erlotinib exposure; therefore, smokers should be advised 
to stop smoking while taking erlotinib. 
 
Drugs that alter the pH of the upper GI tract may alter the sol ubility of erlotinib and reduce its 
bioavailability. Coadministration of erlotinib with omeprazole,  a proton pump inhibitor, decreased the 
erlotinib exposure and maximum concentration by 46% and 61%, respectively; therefore, the 
concomitant use of proton pump in hibitors with erlotinib should  be avoided. 
 Altered coagulation parameters and infrequent reports of bleedi ng events, including gastrointestinal 
and non-gastrointestinal bleedin g, have been reported in patien ts in erlotinib clin ical studies, some 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
25 
 associated with concomitant warf arin administration. Patients t aking warfarin or other coumarin-
derivative anticoagulants will be excluded. 
 
6.3  Availability 
 Erlotinib will be obtained from Astellas by NCI, DCP for use in  this study.  Erlotinib will be handled and 
distributed by the NCI, DCP repo sitory contractor MRI Global (K ansas City, MO).  
 
 
6.4 Agent Distribution 
 Agents will only be released by NCI, DCP after documentation of  IRB approval of the DCP-approved 
protocol and consent is provided  to DCP and the collection of a ll Essential Document s is complete (see 
DCP website for description o f Essential Documents).  
 NCI, DCP-supplied agents may be requested by the Investigator ( or their authorized designees) at each 
Organization. DCP guidelines require that the agent be shipped directly to the institution or site where the agent will be prepared and administered. DCP does not permit the transfer of agents between institutions (unless prior appro val from DCP is obtained). DCP does not automatically ship agents; the 
site must make a request. Agents are requested by completing th e DCP Clinical Drug Request form (NIH-
986) (to include complete shipping  contact information) and faxing or mailing the form to the DCP agent 
repository contractor:  
John Cookinham, MRIGlobal, DCP Che moprevention Agent Repository 
1222 Ozark Street, North Kansas City, MO  64116   Phone: 816-360-3805 FAX:  816-753-5359 Email: NCI.DCP@mriglobal.org  
Emergency telephone: 816-360-3800 
 
6.5  Agent Accountability 
 The Investigator, or a responsib le party designated by the Inve stigator, must maintain a careful record of 
the inventory and disposition of  all agents received from DCP using the NCI Drug Accountability Record 
Form (DARF). The Investigator is required to maintain adequate records of receipt, dispensing and final 
disposition of study agent. This  responsibility has been delega ted to each sites’ licensed pharmacy staff 
as listed on the site-specific Delegation of Tasks document. In clude on receipt record from whom the 
agent was received and to whom study agent was shipped, date, q uantity and batch or lot number. On 
dispensing record, note quantities and dates study agent was di spensed to and returned by each 
participant.  
 
6.6 Packaging and Labeling 
 
Erlotinib is packaged in high de nsity polyethylene bottles, eac h containing thirty ( 30) tablets. Erlotinib 
will be supplied in two bottles, one containing thirty (30) 150 mg tablets and one containing thirty (30) 
25mg tablets, and will be labeled with the following content: product identification and strength, NSC number, tablet count, lot/batch nu mber, expiration date, name a nd address of manufacturer, storage 
information, investigational use  language (Caution: New Drug Li mited by Federal Law to Investigational 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
26 
 Use Only. Keep out of reach of c hildren”), and instructions to take as directed. Prior to dispensing 
investigational product, trial p ersonnel will attach a label co ntaining the participant identification 
number, randomization number, and dispensing date.  
 
6.7 Storage 
 
Erlotinib tablets (150 mg and 25 mg) are supplied in high densi ty, polyethylene bottles and should be 
stored in a secure location.  Storage will be maintained at 25°  C (77°F); excursions  permitted to 15°C - 
30°C (59°F - 86°F).  See USP Controlled Room Temperature. 
 
6.8 Pre-Registration and Registration 
 6.8.1 Participant Pre-Registration  
 
6.8.1.1 To pre-register a partic ipant, the participating site w ill fax or email the completed Pre-
Registration Eligibility Check list to the CPN Registration Offi ce (Fax: 507-284-0885; Email:  
Random01@mayo.edu). The CPN Reg istration Office will enter the data into the CPN-hosted database. 
 
6.8.1.2 At the time of pre-regis tration, the following will be verified: 
• CIRB approval (local context subcommittee) and IRB acknowledgement of CIRB approval and 
informed consent at the registering institution 
• Participant eligibility (including existence of a signed inform ed consent document) 
• Existence of a signed authorizat ion for use and disclosure of p rotected health information (USA 
Institutions only). 
• Study agent is available and Drug Shipment Authorization has be en granted to the registering 
site.     
 
The following will also be recorded: 
• Participant has/has not given pe rmission to collect and store b lood, urine, and/or tissue 
specimens and related informatio n in a Biobank for future use i n research to learn about, 
prevent, treat, or cure cancer  and other health problems. 
• Participant has/has not given pe rmission to cont act him/her or his/her physician to learn about 
the results of these studies. 
• Participant has/has not given pe rmission to send  blood, urine, and/or tissue specimens and 
related information to researc hers at outside institutions. 
• Participant has/has not given pe rmission for information from t he alcohol and tobacco use 
assessment to be used in future health research. 
• Participant has/has not given pe rmission to his/her doctor or their representative to ask them if 
they wish to participate in other research in the future. 
6.8.1.3   Baseline (screening) e valuations must be completed wi thin the guidelines specified on the 
Schedule of Events (See Section 7.1). 
 
6.8.1.4 Registration Office perso nnel will automatically regist er participants separately to the 
translational components of the study (See Section 13).   
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
27 
 6.8.2 Registration 
  6.8.2.1 To register a participan t, the participating site will fax or email the completed Registration 
Eligibility Checklist to the C PN Registration Office (Fax: 507- 284-0885; Email:  Random01@mayo.edu) to 
register all participants. The CPN Registration Office will ent er the data into the CPN-hosted database. 
 6.8.2.2 Intervention cannot begin prior to registration and mus t begin ≤ 14 days from registration. 
 6.8.2.3 Intervention must take p lace at a CPN institution and u nder the supervision of a CPN clinician. 
 
6.8.2.4 Pathology reports confir ming diagnoses must be uploaded  into the database via Medidata Rave 
≤ 30 days post Registration.  
 
6.8.2.5   Descriptive Fact ors collected at baseline:   
• Participating Site 
• Classic or attenuated FAP 
• Baseline aspirin use 
• Severity of duodenal polyposis ( Spigelman stage 2 versus 3). 
 
After the participant has been registered on to the study, valu es of the descriptive factors will be 
recorded.    
6.9 Blinding and Unblinding Methods 
 Not applicable  
6.10 Agent Destruction/Disposal 
 
Per the agreement between NCI, DCP and Astellas Pharma for the supply of erlotinib, returned, unused, 
or undispensed study agent is to be returned to MRIGlobal.    
 Institutions that have policies requiring the immediate destruc tion of returned/unused erlotinib may do 
so under the following conditions : The site’s process for destr uction of patient returns should include 
documentation of the destruction  that includes lot numbers and quantities. This documentation should 
then be provided to MRIGlobal ( NCI.DCP@mriglobal.org ). MRIGlobal will use the information to 
reconcile inventory.  
 
 
At the completion of the study o r upon expiration of the shelf supply, any undispensed study agent will 
be returned to MRIGlobal.  They will reconcile and request perm ission for destruction from Astellas, per 
their requested procedure.  Please following DCP Guidelines for  agent returns and use the agent return 
from the DCP website.  
  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
28 
 7. CLINICAL EVALUATIONS AND PROCEDURES 
 
7.1 Schedule of Events 
 
Evaluation/ 
Procedure Pre-
Registration1 Screening/ 
Baseline1 Registration Month 1  
(+/- 4 days) Months  
2, 4, 5  
(+/- 7 days) Month 3  
(+/- 7 days) Month 6 or 
Early 
Termination 
(+/- 10 days) Follow-Up – 
Month 7 
(+/- 10 
days) 
Informed Consent X         
Assess Eligibility  X       
Medical/Surgical 
History  X        
Physical Exam with vital signs  
(Ht, Wt, temp, pulse, BP)  X   X   X  X   
Alcohol and tobacco use assessments  X      X   
Clinical Laboratory Tests
2  X   X   X  X3 X3 
Urinalysis and urine cotinine
6  X   X   X  X   
EGD/lower GI 
endoscopy with 
biopsies and tattooing  X
7     X7  
Submission of CT imaging and report  X
4     X4  
Research blood and urine collection  X    X X  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
29 
 Evaluation/ 
Procedure Pre-
Registration1 Screening/ 
Baseline1 Registration Month 1  
(+/- 4 days) Months  
2, 4, 5  
(+/- 7 days) Month 3  
(+/- 7 days) Month 6 or 
Early 
Termination 
(+/- 10 days) Follow-Up – 
Month 7 
(+/- 10 
days) 
Pregnancy test, 
serum or urine, if applicable
5  X  X    X  X   
Concomitant Medications  X  X X X X X 
Dispense Study Agent  and 
Medication Diaries   X   X   
Collect/Review Study Agent and 
Medication Diaries      X X  
Was It Worth It (WIWI)       X   
Adverse Events   X  X  X  X  X  X  
Telephone Contact     X   X 
 
1. Pre-Registration and screening must take place ≤ 45 days prior to registration.  
2. Clinical safety and toxicity lab oratory testing includes CBC (w ith 5-part differential, platele ts, and hemoglobin), Albumin, B ilirubin (Total), Calcium, 
Carbon dioxide (Bicarbonate), Chloride, Creatinine, Glucose, Al kaline phosphatase, Potassium, Pro tein (Total), Sodium, ALT/SGP T, AST/SGOT, and 
Blood Urea Nitrogen (BUN).  
3. If any test results ar e outside of instituti onal limits of norm al and clinically-significant, they will be repea ted at Month 7 .  
4. For individuals with desmoid tum ors who have CT imaging at leas t twice yearly as part of their standard clinical  care/surveill ance, CT images and local 
radiologists’ reports will be submitted for central review ≤ 30  days from registration and ≤ 30 days after Month 6  
5. A negative serum or urine pregnancy test (WOCBP only) must be documented ≤ 7 days prior to registration.  If screening pregnan cy test took place ≤ 7 
days prior to registration, it  does not have to be repeated.  
6. Urine cotinine will be tested at b aseline and Month 6/early ter mination only.  
7. The lower GI endoscopy is preferre d but it is optional. It shou ld be performed only if c linically-indicated.    
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
30 
 7.2 Baseline Testing/Prestudy Evaluation 
 
Potentially eligible participants will undergo an educational s ession explaining the study, major 
endpoints, and potential risks. Based on the pre-registration i nclusion and exclusion criteria (See 
Sections 4.1 and 4.2), particip ants will be determined to be po tentially eligible for this trial. After 
appropriate discussions, written informed consent will be obtai ned.  Results of clinically-indicated 
genetic analysis to confirm presence or absence of the APC muta tion will be recorded, if available. 
Following informed consent, part icipants will be pre-registered  to the study.   
 Screening will include a physical exam with vital signs, review  of medical/surgical history, review of 
baseline symptoms and concomitant  medications, alcohol and toba cco use assessments, clinical 
laboratory tests (CBC [with 5-pa rt differential, platelets, and  hemoglobin], Albumin, Bilirubin [Total], 
Calcium, Carbon dioxide [Bicarbo nate], Chloride, Creatinine, Gl ucose, Alkaline phosphatase, Potassium, 
Protein [Total], Sodium, ALT/SGPT, AST/SGOT, and Blood Urea Nit rogen [BUN]), urinalysis and urine 
cotinine, and research blood and urine collection. A pregnancy test will be administered, if applicable. 
 
If still eligible and willing, par ticipants will undergo an eso phagogastroduodenoscop y (EGD) plus lower 
GI endoscopy with biopsies and ta ttooing.  The lower GI endosco py is preferred but optional (See 
Section 7.6 for details).  
 
For individuals with desmoid tum ors who have CT imaging at leas t twice yearly as part of their standard 
clinical care, CT images along wi th the local radiologist’s rep ort from before and after intervention will 
be submitted for central review.  Screening must be completed ≤ 45 days prior to registration.  After registration, participants will be dispensed a 3-month supply of st udy agent (See Section 5.2), a medication and symptom diary, and 
appropriate instructions.  
7.3 Evaluation During Study Intervention 
 At Month 1 (+/-4 days), a visit will take place including physi cal exam with review of vital signs, review of 
adverse events and concomitant me dications, clinical laboratory  tests (CBC [with 5- part differential, 
platelets, and hemoglobin], Albumin, Bilirubin [Total], Calcium , Carbon dioxide [Bicarbonate], Chloride, 
Creatinine, Glucose, Alkaline pho sphatase, Potassium, Protein [ Total], Sodium, AL T/SGPT, AST/SGOT, 
and Blood Urea Nitrogen [BUN]), and urinalysis.  The medication  and symptom diaries will be reviewed 
to confirm participant understanding of the instructions, but t hey will not be collected. 
 
Participants will be contacted b y phone at Months 2, 4, and 5 ( +/-7 days) to review adverse events and 
concomitant medications. 
 At Month 3 (+/-7 days), a visit will take place including physi cal exam with review of vital signs, review of 
adverse events and concomitant me dications, clinical laboratory  tests (CBC [with 5- part differential, 
platelets, and hemoglobin], Albumin, Bilirubin [Total], Calcium , Carbon dioxide [Bicarbonate], Chloride, 
Creatinine, Glucose, Alkaline pho sphatase, Potassium, Protein [ Total], Sodium, AL T/SGPT, AST/SGOT, 
and Blood Urea Nitrogen [BUN]), and urinalysis. Research blood and urine will be collected. A pregnancy test will be performed, if applicable. Any unused agent will be  collected and a new supply (as described 
in Section 5.2) dispensed.  Medication and symptoms diaries wil l be collected and new ones provided. 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
31 
 7.4 Evaluation at Completion of Study Intervention 
 
At Month 6 (+/-10 days), a post- intervention visit will take pl ace, including physical exam with review of 
vital signs, review of adverse ev ents and concomitant medicatio ns, follow-up alcohol and tobacco use 
assessments, clinical laboratory tests (CBC [with 5-part differential, platelets, and h emoglobin], Albumin, 
Bilirubin [Total], Calcium, Carbon dioxide [Bicarbonate], Chlor ide, Creatinine, Glucose, Alkaline 
phosphatase, Potassium, Protein [Total], Sodium, ALT/SGPT, AST/ SGOT, and Blood Urea Nitrogen 
[BUN]), urinalysis and urine coti nine, and research blood and u rine collection. A pregnancy test will be 
performed, if applicable. Any unused agent and all medication/symptom diaries will be collected. Participants will undergo an EGD  plus lower GI endoscopy with clearing of all polyps, according to 
institutional standards of care, plus research biopsies.  All e fforts should be made to confirm the same 
endoscopist performs the pre- an d post-intervention endoscopy p rocedures. 
 
7.5 Post-intervention Follow-up Period 
Participants should be seen in the clinic or contacted by telep hone to determine if  any serious or non-
serious adverse events have occu rred within 30 days (±7 days) o f termination of study participation, 
whether they complete the 6-mont h trial or not.  If abnormal an d clinically-significant laboratory values 
are found at the end of the study , these will be repeated at this time point.  If all l ab values are normal 
at Month 6, no additional laboratory tests will be done.  
End-of-Treatment Evaluations due to early withdrawal 
 
If a participant discontinues us e of the study medication prior  to 6-month trial completion, the following 
will be performed:   
a. Reason for discontinuation will be  determined and recorded in p articipant’s file. 
b. Clinic visit for history and physical exam, and EGD and lower G I endoscopy (if intact 
colon or rectal stump).   
c. Management of adverse events acc ording to institutional standar ds of good clinical 
practice and notification of NCI, DCP medical monitor 
d. Review of concomitant medicati ons, compliance assessment, and r eturn of unused 
study agent  
e. All blood tests and urinalysis/urine cotinine will be performed .  Research blood and 
urine collection will be perfo rmed if consent provided. 
 
7.6 Methods for Clinical Procedures 
 
Endoscopic Screening: Participants will be monitored per institutional standards of g ood clinical practice 
(i.e. blood pressure, heart rate, pulse oxygenation) and then a ppropriately sedated.  The examination 
and measurement components of th e endoscopy procedures will be implemented in a manner 
consistent with the FAPEST study, recently reported in JAMA,20 as outlined in brief below.  
 Upper GI Endoscopy:  The duodenum will be evaluated by  forward-viewing and/or side- viewing 
gastroscopes (with still and vid eo documentation). Esophagogast roduodenoscopy (EGD) will be 
performed and a tattoo placed 10 cm distal to the duodenal bulb  to define a region heretofore referred 
to as the duodenal segment, which will extend from the duodenal bulb distally to the tatt oo. Endoscopic 
tattooing has been widely employe d in previous research protoco ls and is clinically used by many 
authorities.
25, 26 Intramucosal injections of 0.5 ml to 2 ml are used as necessar y to mark the mucosa.  All 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
32 
 participants will have screening/ baseline and final study endpo int (Month 6) UGI endoscopy as part of 
this trial.  
 
Lower GI Endoscopy (preferred but optional):  Willing participants will be evaluated via flexible 
proctosigmoidoscopy during the screening/baseline examination a nd final study endpoint (Month 6) 
evaluation. Flexible sigmoidoscopy will be used to examine the pouch, rectum (IRA), or rectal stump 
(IPAA) in FAP or attenuated FAP individuals who have undergone colectomy.  For consistency, those 
with a rectum or rectal stump, b iopsies of normal tissue will o nly be done if 10 cm of rectum (from the 
anal verge) is present.  
 
Video Recording and ca pture of still images:   All procedures will be recorde d in high definition using 
Medicapture (or comparable) reco rds to allow for blinded physic ian review as a secondary endpoint.  
Still images are highly recommend ed but not required.  Still im ages (photos) should be taken at baseline 
and Month 6 in the center of the  lumen at 1 cm increments durin g withdrawal from the duodenum.  Any 
large polyps, particularly those  that are biopsied for Spigelman staging at baseline, should also be 
photographed with the biopsy forceps visible to provide a refer ence for size. 
 
Pre-treatment Endoscopic Assessment. Topical lidocaine will be used for pharyngeal anesthesia. Conscious sedation will be admini stered by the endoscopist-inve stigator, as is the current clinical 
standard of practice.  Medicines will primarily consist of mida zolam and fentanyl, but other sedatives 
are occasionally needed.  Endosc opy will be performed in the st andard fashion.  A side-viewing 
endoscope (preferred) will be use d specifically to examine and record the size of the ampulla of Vater in 
the duodenum.  If this cannot be done, then viewing with the fo rward viewing endoscope is acceptable.  
Biopsies of the ampulla of Vater will only be obtained if it ap pears abnormally large or suspicious for 
malignancy.  The size, location, and number of polyps will be d etermined and recorded, consistent with 
procedures that have been used extensively in polyp studies. Each polyp in the duodenal segment will be measured, mapped, and recorded at 1-cm intervals in the 10-c m segment.  In the rectum, each polyp 
will be measured and recorded.  
Counting and mapping polyps will be performed prior to collecti on of any biopsies or removal of any 
polyps. 
 At baseline, at least one polyp will be biopsied and sent for l ocal histological analysis for eligibility 
determination and Spigelman stage determination.  This specimen  will be collected and processed 
according to institutional standa rd operating procedures.  Any lesions containing high-grade dysplasia or 
cancer will result in a referral to surgery and oncology, and, exclusion of the patient from the study.  Any 
lesions that are ≥ 10mm and/or worrisome for high grade dysplas ia or cancer in the opinion of the 
endoscopist, should be removed or sampled according to institut ion standards of care. This should be 
noted on the endoscopy report. Pa rticipants with extensive, but  quantifiable, duodenal polyposis will 
not be necessarily excluded from the study unless histological analysis reveals high grade dysplasia or 
cancer.  These specimens are not among the specimens being coll ected for research purposes.  
 For research purposes, four endo scopic biopsies of grossly norm al duodenal mucosa and one (for 
Spigelman 2) or two (Spigelman 3) endoscopic biops(ies) of duod enal polyp will be obtained from all 
participants at screening/baseline and end of the study (Month 6
 ).  One biopsy from both normal and 
polyp at each time point will be p laced in RNA later, and the remaining specimens will be snap frozen in 
liquid nitrogen.  Note:  if Spigelman Stage is not known at the  time of the baseline endoscopy, the 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
33 
 endoscopists should use their best clinical judgement regarding  Spigelman 2 versus Spigelman 3 based 
on the size and number of polyps .  If the subsequent pathology assessment differs from the 
endoscopist’s assessment, a note-to-file will be created for th e participant’s file. 
 
Polyps on the ampula of Vater should be included in the mapping  and counting process. These polyps 
should be biopsied if worrisome.  At Month 6, the side-viewing e ndoscope (preferred) will be used  specifically to examine and record the 
size of the ampulla of Vater in the duodenum.  If this cannot b e done, then viewing with the forward 
viewing endoscope is acceptable.   
 
If there are at least 10 cm of rectum, four endoscopic biopsies  of normal rectal mu cosa will be obtained 
in patients with a rectal stump or intact rectum at screening/baseline and end of the study (Month 6).  One biopsy of rectal mucosa at each time point will be placed in RNA later, and the remaining specimens 
will be flash frozen in liquid nitrogen.  
 
For individuals with desmoid tum ors who have surveillance CT (w ith contrast) imaging at least twice 
yearly as part of their standard  clinical care, CT images along  with the local radiologist’s report will be 
submitted for central radiology review, which will take place a t the University of Utah.  The radiology 
reviewer (MEH) will be blinded a s to the time point (pre-intervention versus post-intervention) and 
enrolling institution.   
 
8.  CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION 
 
8.1 Primary Endpoints  
 
• Polyp Burden:   To assess the mean  percent change in duodenal p olyp burden (sum of diameters 
from all polyps) from baseline to 6 months post-intervention  as assessed by 
esophagogastroduodenoscopy (EGD) for FAP subjects receiving wee kly erlotinib.  The hypothesis 
is that weekly erlotinib will significantly reduce duodenal polyp burden after 6 months of 
treatment.   
• Adverse events (if polyp burden shows a significant decrease fr om baseline):  To assess the 
grade 2/3 adverse event rate in this population and compare it to historical data.  The 
hypothesis is that weekly erlotinib will significantly reduce the grade 2/3 AE rate compared to historical control data.   
8.2      Secondary Endpoints 
 
• To evaluate all adverse events associated with the weekly erlotinib; 
• To assess the absolute and percent  change in duodenal polyp num ber from baseline to 6 
months;   
• To assess the absolute and percent changes in lower gastrointes tinal polyp burden and number 
for the subset of participants with ileal pouch anal anastomosi s (IPAA) or ileo-rectal anastomosis 
with rectal stump (anticipated to be approximately 70% of regis tered cohort); and 
• To assess the absolute and percent change in desmoid tumor size  in participants who have 
baseline and follow up CTs performed as part of their standard of care (anticipated to be approximately 30% of the registered cohort); 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
34 
 • Gene expression profiles in duodenal adenomas and uninvolved ti ssue will be compared 
between baseline and endpoint samples using negative binomial s tatistics (DESeq2): 
o Identify differentially expressed genes between duodenal polyps  and uninvolved tissue 
at endpoint compared to baseline; 
o Evaluate the effect of weekly erl otinib on EGFR and Wnt target gene expression in 
duodenal adenomas  
o Evaluate the effect of weekly erlotinib on immune response sign aling in duodenal 
adenomas and uninvolved tissue.  Global gene expression (RNA tr anscriptome) will be 
measured by RNA sequencing. This global RNA analysis includes a ll immune response 
genes. These analyses will be don e by Dr. Don Decker, Huntsman Cancer Institute, 
University of Utah.  
 
8.3 Off-Agent Criteria  
 
Participants may stop taking the study agent due to: completion  of the planned intervention period, 
development of an adverse event or serious adverse event, inade quate agent supply, noncompliance, 
use of concomitant medications, medical contraindication, refus al, ineligibility (see Section 8.4), major 
treatment violation (see Section 8.4) or alternative treatment.  Participants will continue to be followed, 
if possible, for safety accordi ng to the intended schedule of e vents (see Section 7).  
 
Participants discontinuing the p lanned intervention prematurely  will be encouraged to complete the 
Post-Intervention Evaluation tests and procedures as described below (if participant does not refuse, is 
not lost to follow-up, or unless it is clinically contraindicat ed).  
 
If a participant discontinues study agent before Month 3 due to  adverse events, it is preferable to 
continue AE assessment through Mo nth 7.  This can be done by phone, if preferred.  Endoscopies and 
blood testing do not need to be performed unless clinically ind icated.   
 If the participant discontinues study agent after the Month 3 t ime point, perform the Month 6 visit, 
including endoscopy, within 10 days of discontinuing agent.  If  it cannot be done within 10 days, 
schedule the visit and procedures  as close as possible to this time point.   
 See Section 8.4 for further details as to data submission for p articipants deemed Ineligible after starting 
treatment or classified as a Majo r Treatment Violation (i.e., p rotocol requirements regarding 
intervention during the first week post-registration were sever ely violated).  
 
8.4 Off-Study Criteria 
 
Participants may go “Off-Study” for the following reasons: development of an advers e event or serious 
adverse event, death, lost to follow-up, participant withdrawal , physician decision, protocol violation, 
complete study, or other (with d etailed comments provided). Rea son(s) will be noted in the participant’s 
research records, with the prima ry reason clearly identified. T he participant will be classified as (Off 
Study/Off Agent). Data submission and follow-up after participa nts are determined to be “Off-Study/Off-
Agent” for specific situations is noted below: 
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
35 
 A registered participant is deemed ineligible if the participan t did not satisfy each and every eligibility 
criterion at the time of study e ntry, for example, identified b ased on an audit or through the case 
evaluation process. 
 
• If participants received study intervention, on-study materials  and all data up until the 
point of confirmation of ine ligibility will be submitted. 
• If participants did not receive study intervention, on-study materials must be submitted. No 
further data submission is necessary. No follow-up is required.  
 Major Treatment Violation: A reg istered participant is deemed a s being in major treatment violation by 
the coordinating center, if the p articipant’s very first treatment/intervention administration is so grossly 
administered in error, that the participant’s data can no longer be used for the primary endpoint. These 
cases are typically rare.  
• On-study material and all data u p until the point of confirmati on of a major violation must be 
submitted. 
 Cancel/Participant Withdrawal: A registered participant is deem ed a cancel if he/sh e refuses the study 
or withdraws consent before any s tudy intervention is given.  O n-study material must be submitted. The 
Off Study case report form must  be submitted.    No follow-up i s required. 
 
8.5 Study Termination 
 NCI, DCP as the study sponsor ha s the right to discontinue the study at any time.  
 
9. CORRELATIVE/SPECIAL STUDIES 
 9.1 Rationale for Me thodology Selection  
 
See Biomarker Methods Development Report. 
 
9.2 Comparable Methods  
 Methodology for this study is co nsistent with the FAPEST trial,
20 which should result i n data that can be 
compared to existing data. 
 
10. SPECIMEN MANAGEMENT  
 
10.1 Laboratories 
 
Clinical laboratory evaluations will take place at each institu tion’s clinical laboratories as listed on the 
study-specific FDA form 1572.  These include blood chemistry, h ematology, and urinalyses. 
 RNA extractions and RNA sequencing: Don A. Delker, Ph.D., Laboratory Manager Division of Gastroenterology, Hepatology and Nutrition 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
36 
 School of Medicine, University of Utah 
30 North 1900 East, Salt Lake City, UT 84132 Phone: 801-585-0328 Email: don.delker@hsc.utah.edu 
 
10.2 Collection and Handling Procedures 
  
Research blood kits for shipping blood, urine, and tissue for a ll research analyses will be provided by BAP 
Kit Building (Biospecimen Accessioning and Processing Core Faci lity).  Detailed colle ction, handling, and 
shipping instructions will be included with each kit.  Particip ating Sites may obtain research kits by faxing 
the BAP Kit Supply Order Form to the number provided (found in the Forms Packet).  At least two weeks 
should be allowed to receive the shipping kits.  Kits will be s ent via FedEx® Ground at no additional cost 
to the participating institution s.  They will not be forwarded by FedEx® rush delivery service unless the 
participating institution provid es their own FedEx® account num ber.  CPN will not cover the cost for rush 
delivery of kits. Because charges  are incurred for all outgoing  kits, a small, but sufficient, supply of 
specimen collection kits should be ordered prior to participant  entry. 
 
• All sections of the requisition f orm, specimen submission CRFs, and specimen collection labels 
must be completed and legible.  
• Specimens should be sent overnig ht via FedEx® on dry ice.  All specimens must be shipped to 
the address provided on the specimen shippers.   
• All specimens will be shipped in  compliance with the Internatio nal Air Transport Association 
(IATA) Dangerous Goods Regulations. 
 
10.2.1 Clinical Blood and Urine Specimens 
 
Clinical blood and urine specimen s will be collected and proces sed according to e ach institution’s 
internal standard operating proc edures.  Results will be report ed on the appropriate case report forms. 
 10.2.2 Research Blood a nd Urine Specimens 
 Using the required BAP kits, an optional blood s pecimen (one 10  mL no additive red-topped tube, and 
one 10 mL purple topped tube) w ill be collected at screening/baseline and end of study (Month 6), 
processed into serum, plasma, a nd buffy coat, frozen, and shipp ed to BAP (see below) for storage for 
future research.   
 
An optional urine specimen will also be collected, frozen, and shipped on dry ice, overnight to the BAP 
freezer.  Specimens will be frozen at -20
o or colder and shipped on dry ice, M-F, overnight to the BAP Fr eezer: 
 
Biospecimens Accessioning and Processing (BAP) Freezer 
ST SL-16, 150 Third Street Sou thwest, Rochester, MN  55902 
   Questions should be addressed to: 
  Roxann Neumann, Biospecimens Resource Manager 
Phone: 507-538-0602; Email: N eumann.roxann@mayo.edu 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
37 
 10.2.3 Tissue Specimen Collection and Submission  
 
At baseline, at least one polyp will be removed and sent for lo cal histological analysis for eligibility 
determination and Spigelman stage determination (See Section 7. 6).  This specimen will be collected and 
processed according to instituti onal standard operating procedu res. 
 Four endoscopic biopsies of norma l duodenal mucosa and one (for  Spigelman 2) or two (Spigelman 3) 
endoscopic biops(ies) of duodena l polyp will be obtained from a ll participants at screening/baseline and 
end of the study (Month 6).  One  biopsy from both normal and polyp at each time point will be placed in 
RNA later, and the remaining spec imens will be snap frozen in l iquid nitrogen. 
 Four endoscopic biopsies of norma l rectal mucosa will be obtain ed in patients with a rectal stump or 
intact rectum at screening/base line and end of the study (Month  6).  One biopsy of rectal mucosa at 
each time will be placed in RNA later, and the remaining specim ens will be flash frozen in liquid 
nitrogen.
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
38 
 Research Specimen Summary  
Specimen Time Point(s) Processing Shipping 
Optional research 
blood: one 10 mL 
EDTA lavender -
topped and one 10 
mL red-topped tube Baseline/screening, 
Month 3, and 
Month 6 Utilize BAP kits; Process into r ed-top tube into serum at site.  
Process lavender-topped tube into plasma and buffy coat at site . 
Freeze all specimens.   Place sample type on the label: P=plasm a; B-
Buffy; S=Serum Ship to BAP FedExTM overnight, M-F, on 
dry ice. BAP will accession and store at -80
oC. 
Optional research blood: Two 10 mL 
EDTA lavender-
topped tube Baseline/screening, 
Month 3, and Month 6 Utilize BAP kit.  Centrifuge, aliquot into intermediate tube, a nd 
centrifuge again to produce pl atelet poor plasma (PPP) per 
institutional lab procedures. Be sure to not disturb the residu al 
blood cells carried over from the first centrifugation step whe n 
aliquoting PPP.  See BAP kit ins tructions for details. Freeze. Ship to BAP FedEx
TM overnight, M-F, on 
dry ice. BAP will accession and store at -80
oC. 
Optional urine specimen Baseline/screening, 
Month 3 and 
Month 6 Utilize BAP kit; aliquot from co llection container to tubes pro vided. 
Freeze. Ship to BAP FedEx
TM overnight, M-F, on 
dry ice. BAP will accession and store at -80
oC. 
Tissue if Spigelman 2: Baseline/screening and Month 6 1. Four biopsies of normal duodenal mucosa and one biopsy of 
duodenal polyp. 
2. Place one normal duodenal mucosa biopsy and one polyp in RNAlater. Refrigerate at 4-6
oC or snap freeze. 
3. Snap freeze remaining three specim ens in separate cryovials in 
liquid nitrogen.  
4. Make sure labels distinguish nor mal duodenal mucosa versus 
polyp specimens. Ship frozen specimens to BAP FedExTM 
overnight, M-F, on dry ice.   
 
Ship specimen in RNALater to BAP on a 
cold pack (or dry ice if  frozen).  Accession.  
Store specimens at -80oC until requested.  
Tissue if Spigelman 3: Baseline/screening 
and Month 6 1. Four biopsies of normal duodena l mucosa and two biopsies of 
duodenal polyps. 
2. Place one normal duodenal mucosa biopsy and one polyp in RNAlater. Refrigerate at 4-6
oC or snap freeze 
3. Snap freeze all remain ing specimens in separate cryovials in 
liquid nitrogen (three normal duodenal mucosa and one polyp).  
4. Make sure labels distinguish nor mal duodenal mucosa versus 
polyp specimens. Ship frozen specimens to BAP FedExTM 
overnight, M-F, on dry ice.   
 
Ship specimens in RNALater to BAP 
FedExTM overnight, M-F, on a cold pack 
(or dry ice if frozen).  Accession.  Store 
specimens at -80oC until requested. 
Tissue if a rectal stump or intact 
rectum: Baseline/screening 
and Month 6 1. Four biopsies of normal rectal mucosa 
2. Place one rectal mucosa biopsy i n RNAlater and refrigerate at 
4-6
oC or snap freeze 
3. Snap freeze the three remainin g rectal biopsies in liquid 
nitrogen. Ship frozen specimens to BAP FedExTM 
BAP FedExTM overnight, M-F, on dry ice.   
Ship specimens in RNALater to BAP FedEx
TM overnight, M-F, on a cold pack 
(or dry ice if frozen).  Accession.  Store 
specimens at -80oC until requested. 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
39 
 10.3 Labeling and Shipping Instructions 
 
The pre-addressed shipping labels will be provided with the spe cimen kits.  Site team s are cautioned to 
make sure the correct specimen is  sent to the correct location for analysis. 
      All specimens must be labeled with the study number, participan t ID, participant init ials (if allowed per 
institutional policy), type of sp ecimen (normal mucosa versus p olyp), source of specimen (duodenum 
versus rectum), additive (RNALater versus none/snap frozen), da te and time of colle ction. Abbreviations 
are allowed, if legible (see kit requisition form or instructio ns). 
 Example:   MAY2016-07-01 
Month 6 CPN00023 
   T O M 
   mm/dd/2016, 14:30    Duodenal polyp 
   R N A l a t e r  
 
All sections of the requisition form and specimen collection la bels must be completed and legible.   
Specimen collection vial labels should match the requisition fo rm exactly. 
 
All specimens should be sent over night (Monday through Friday) via FedEx® on dry ice or on a cold pack 
(See Research Specimen Summary Table, Section 10.2). Site staff  will send an email wi th FedEx tracking 
number to the Biospecimen Resou rce Manager so arrangements can be made to receive the specimens 
and place immediately in appropriate storage facilities.  Excep tions for holidays will be communicated in 
advance to participating organiza tions.  All specimens must be shipped to the address provided on the 
specimen shippers and listed above (See Section 10.2).  
 
10.4 Tissue Banking 
 Biologic specimens collected dur ing the conduct of each clinica l trial that are not used during the course 
of the study will be considered deliverables under the contract  and thus the property of the NCI.  
 At study completion, remaining frozen biologic specimens will be labeled (study number, participant ID number, specimen type, specimen number, date of collection) bat ched, and shipped (o vernight, M-F) for 
storage (until request is receiv ed to transfer to DCP Biospecim ens Repository) to: 
 
Biospecimens Accessioning and Processing (BAP) Freezer 
ST SL-16, 150 Third Street Sou thwest, Rochester, MN  55902 
 At study completion, NCI reserves the option to either retain or relinquish ownership of the unused 
biologic specimens. If NCI retains ownership of specimens, the Contractor shall collect, verify and 
transfer the requested biologic specimens from the site to a NC I-specified reposito ry or laboratory at 
NCI’s expense.  
  
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
40 
 11. REPORTING ADVERSE EVENTS  
 
DEFINITION: AE means any untowar d medical occurrence associated with the use of a drug in humans, 
whether or not considered drug r elated. An AE can therefore be any unfavorable and unintended sign), 
symptom, or disease temporally a ssociated with participation in  a study, whether or not related to that 
participation. This includes all deaths that occur while a part icipant is on a study. 
 
Please note that all abnormal cli nical laboratory values that are determined to be of clinical significance 
based on a physician’s assessment are to be reported as AEs. Th ose labs determined to be of no clinical 
significance or of unknown clinical significance (per the physi cian’s assessment) should not be reported 
as AEs. Any lab value of unknown clinical significance should c ontinue to be investigated/followed-up 
further for a final determination, if possible.  A list of AEs that have occurred or might occur  can be found in §6.2 Reported Adverse Events and 
Potential Risks, as well as the I nvestigator Brochure or packag e insert.  
 
11.1 Adverse Events 
 
11.1.1 Reportable AEs 
 
All AEs that occur after the informed consent is signed and bas eline assessments are completed 
(including run-in) must be recorded on the AE CRF (paper and/or  electronic) whether or not related to 
study agent.  
11.1.2 AE Data Elements: 
 The following data elements are required for AE reporting. 
• AE verbatim term 
• NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) AE term 
(MedDRA lowest level term) 
• CTCAE (MedDRA) Syste m Organ Class (SOC) 
• Event onset date and event ended date 
• Treatment assignment code ( TAC) at time of AE onset 
• Severity grade 
• Attribution to study agent (relatedness) 
• Whether or not the event was reported as a SAE 
• Whether or not the subject dropped due to the event 
• Outcome of the event 
 11.1.3  Severity of AEs 
   
11.1.3.1  Identify the AE using the CTCAE version 4.0. The CTCAE provides descriptive terminology (MedDRA lowest level term) and a grading scale for each AE list ed. A copy of the CTCAE can be found at 
http://ctep.cancer.gov/protocolDevelopment/electronic_applicati ons/ctc.htm  
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
41 
 AEs will be assessed according to  the grade associated with the  CTCAE term. AEs that do not have a 
corresponding CTCAE term will be assessed according to the gene ral guidelines for grading used in the 
CTCAE v4.0. as stated below.  
 
CTCAE v4.0 general severity guidelines:  
 
Grade Severity Description  
1 Mild Mild; asymptomatic or mild symptoms; clinical or diagnos tic observations only; 
intervention not indicated. 
2 Moderate Moderate; minimal, local or noninvasive intervention  indicated; 
limiting age-appropriate instrumental activities of daily livin g (ADL)*. 
3 Severe Severe or medically significant but not immediately li fe-threatening; 
hospitalization or prolongation of hospitalization indicated; d isabling; limiting self-
care ADL**. 
4 Life-threatening Life-threatening consequences; urgent interv ention indicated. 
5 Fatal Death related to AE. 
   
ADL 
 *Instrumental ADL refers to preparing meals, shopping for groce ries or clothes, using the telephone, 
managing money, etc. 
 
**Self-care ADL refers to bathing, dressing and undressing, fee ding self, using the toilet, taking 
medications, and not bedridden. 
 
11.1.4 Assessment of relatio nship of AE to treatment 
  
The possibility that t he AE is related to study agent will be c lassified as one of the following: not related, 
unlikely, possible, probable, or definite.   11.1.5 Follow-up of AEs 
 
All AEs, including lab abnormalit ies that in the opinion of the  investigator are clinically significant, will be 
followed according to good medical practices and documented as such.  
 
11.2 Serious Adverse Events  
 
11.2.1 DEFINITION: Regulations a t 21 CFR §312.32 (revised April  1, 2014) defines an SAE as any 
untoward medical occurrence that at any dose has one or more of  the following outcomes: 
 
• D e a t h  
• A life-threatening AE 
• Inpatient hospitalization or prolongation of existing hospital ization 
• A persistent or significant incapacity or substantial disrupti on of the ability to perform normal 
life functions 
• A congenital anomaly or birth defect 
• Important medical events that m ay not be immediately life-thre atening or result in 
death or hospitalization should a lso be considered serious when , based upon 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
42 
 appropriate medical judgment, they may jeopardize the patient a nd may require 
intervention to prevent on e of the other outcomes. 
 
11.2.2  Reporting SAEs to DCP 
 
11.2.2.1 The Lead Organization and all Participating Organizati ons will report SAEs fo llowing the current, 
active DCP SAE reporting SOP available at this location: http://prevention.cancer.gov/clinical-
trials/clinical-trials-management /protocol-information-office/pio-instructions-and-tools/2012-consortia. 
 
11.2.2.2  Contact the DCP Medic al Monitor by phone within 24 ho urs of knowledge of the event.  
 
Gary Della’Zanna, D.O., M.Sc.  
National Institutes of Health, National Cancer Institute  Division of Cancer Prevention  
9609 Medical Center Drive  
Bethesda, MD 20892  Phone: 240-276-7042  Fax (with cover sheet, Attn: Dr. G. Della’Zanna): 240-276-7848  
Email: dellazannagj@mail.nih.gov  
 Include the following informatio n when calling the Medical Moni tor: 
• Date and time of the SAE 
• Date and time of the SAE report 
• Name of reporter 
• Call back phone number 
• Affiliation/Institution conducting the study 
• DCP protocol number 
• Title of protocol 
• Description of the SAE, including attribution to drug 
 Guidance for the process of coding the SAE can be obtained by c ontacting the NCI MD Help Desk:  
adeersmd@tech-res.com  
 11.2.2.3 The Lead Organization and all Participating Organizati ons will submit SAE reports, following 
the current, active DCP SAE repor ting SOP within 48 hours of le arning of the event: 
 
1. DCP Medical Monitor: dellazannagj@mail.nih.gov    
2. DCP’s Regulatory Contractor CCS Associates, Inc.: safety@ccsainc.com    
3. CPN Operations Office: cancerpreventionnetwork@mayo.edu    
   Follow up information should also  be sent to all of the above. 
 11.2.2.4 The DCP Medic al Monitor and CCSA regulatory and safety  staff will determine which SAEs 
require FDA submission as IND safety reports. 
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
43 
 11.2.2.5 The Lead Organization and all Participating Organizati ons will comply with applicable regulatory 
requirements related to reporting SAEs to the IRB/IEC.  
 11.2.3 Follow-up of SAE  
Site staff should send follow-up reports as requested when addi tional information is available. Follow-up 
information should be submitted to DCP as soon as available.  S AEs will be treated according to 
institutional standards of good  clinical practice and followed to resolution.   
 
12. STUDY MONITORING  
 
12.1 Data Management 
 
The Mayo Clinic Cancer Center da tabase will be the database of record for the protocol and subject to 
NCI and FDA audit.  Minimum Data Sets will be submitted to DCP per contract requirements.  Please see 
2012 CPN Master Data Management Plan. 
 
12.2 Case Report Forms 
 Participant data will be collect ed using protocol-specific case  report forms (CRF) utilizing NCI-approved 
Common Data Elements (CDEs). The approved CRFs will be used to create the electronic CRF (e-CRF) 
screens for data entry into the Mayo Clinic Cancer Center database. Amended CRFs will be submitted to the DCP Protocol Information Office for review and approval.  
12.3 Source Documents 
 A source document is any docum ent, form, or record where specific participants’  data are first recorded.  
FDA [21 CFR 312.62 (b)] requires that the investigator “...prepare and maintain accurate case histories 
designed to record all observatio ns and other data pertinent to  the investigation on each individual 
treated with the investigational  agent or employed as a control  in the investigation.” Among many other 
items, source docu ments include:  
• Inpatient and outpatie nt medical records  
• Progress notes  
• Consults  
• Nursing notes  
• Pathology reports  
• Endoscopy reports  
• Medicine/radiation administration records  
• Surgical reports  
• Laboratory reports  
• Admission forms  
• Flow sheets and worksheets t hat are signed and dated  
• Protocol or study road maps  
• Appointment books  
• Participant diaries/calendars 
• Blood and tissue collection/submission and requisition forms (s igned and dated).  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
44 
 12.4 Data and Safety Monitoring Plan 
 
The CPN Master DSMP is applicable to all studies within the CPN Consortium and provides detailed information regarding data and safety monitoring for this study .  The trial will be monitored closely for 
occurrence of adverse events by the study team and by the Mayo Clinic Cancer Center Data Safety 
Monitoring Board (DSMB). The DSM B (along with the study Medical  Monitor) will be consulted 
regarding whether or not accrual should be suspended to allow f or investigation in the occurrence of 
severe adverse events, particula rly for those that are possibly , probably, or definitely related to the 
study agent.  
12.5 Sponsor or FDA Monitoring 
 The NCI, DCP (or their designee), pharmaceutical collaborator ( or their designee), or FDA may 
monitor/audit various aspects o f the study. These monitors will  be given access to facilities, databases, 
supplies and records to review and verify data pertinent to the study.   
12.6 Record Retention 
 Clinical records for all particip ants, including CRFs, all sour ce documentation (containing evidence to 
study eligibility, history and physical findings, laboratory da ta, results of c onsultations, etc.), as well as 
IRB records and other regulatory documentation will be retained by the Investigator in a secure storage 
facility in compliance with Healt h Insurance Port ability and Ac countability Act (HIPAA), Office of Human 
Research Protections (OHRP), Food  and Drug Administration (FDA)  regulations and guidances, and 
NCI/DCP requirements, unless the standard at the site is more s tringent. The records for all studies 
performed under an IND will be mai ntained, at a minimum, for tw o years after the approval of a New 
Drug Application (NDA). For NCI/ DCP, records will be retained for at least three years after the 
completion of the research. NCI will be notified prior to the planned destruction of any materials. The 
records should be acce ssible for inspection and copying by auth orized persons of the Food and Drug 
Administration. If the study is done outside of the United Stat es, applicable regulat ory requirements for 
the specific country participating in the study also apply.  
12.7 Cooperative Research and Deve lopment Agreement (CRADA)/Clinical Trials 
Agreement (CTA) 
 Not applicable    
13. STATISTICAL CONSIDERATIONS 
 
13.1 Study Design/Description 
 This is a single arm Phase II trial designed to assess the effe ct of weekly erlotinib among FAP subjects.  
The primary objective of this trial is to assess the mean perce nt change in duodenal polyp burden (sum 
of diameters from all polyps) from baseline to 6 months post-in tervention for FAP subjects receiving 
weekly erlotinib.  The hypothesis is that weekly erlotinib will  significantly reduce duodenal polyp burden 
after 6 months of treatment.  If  a significant reduction in pol yp burden is shown after 6 months of 
treatment, we will also assess th e grade 2/3 adverse event rate  in this population and compare it to 
historical data.  The hypothesis is that weekly erlotinib will significantly reduce the grade 2/3 AE rate 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
45 
 compared to historical control d ata.  Statistical considerations regarding sample size and study power 
are based on this primary study o bjective.  Secondary endpoints  will evaluate all ad verse events, assess 
the absolute and percent change i n duodenal polyp number from b aseline to 6 months, and assess the 
absolute and percent changes in lower gastrointestinal polyp bu rden and number within patient subsets 
of interest.   
 
There is limited Quality of Life (QOL) data on participants who participate in chemoprevention trials and 
we intend to create a databank of QOL information by administer ing the “Was It Worth It” (WIWI) 
questionnaire at trial completion across multiple  trials. We will seek to evaluate participant perception 
of their experience in trial par ticipation once we have a reasonable amount of information (large 
enough sample size). Since participants who participate in thes e chemoprevention trials are high risk but 
otherwise healthy, the WIWI tool would help answer simple quest ions about participants’ assessment of 
whether or not participation in this trial was “worth it.”  
 
13.2 Randomization/Stratification  
 
There will be no randomization o r stratification for this study .  This study will be a  single arm Phase II 
trial, where all subjects wil l be accrued in one stage.   
 
13.3  Accrual and Feasibility 
 
The study design requires a total of up to 70 participants for screening evaluation with approximately 60 moving forward to regis tration and intervention due to anticipa ted screen failures of approximately 
15%.  We further expect up to 15% of participants to drop out o r otherwise become non-evaluable by 6 
months such that approximately 50 subjects should be evaluable for the primary endpoint.  We expect 
to enroll an average of 1 participant per month for each of the  participating CPN sites, for an overall 
registration rate of approximately 6 participants per month.  W ith this accrual rate  and with a 6 month 
ramp up for participating organi zations, we plan to complete ac crual in about 18 months, which includes 
2 months for planned slowing of e nrollment due to holidays, etc .  Accounting for patient follow-up, data 
entry, and analysis, the study s hould be completed within appro ximately 2.5 years.   
 
Planned Accrual Estimates 
 
  
Racial Categories DOMESTIC PLANNED ENROLLMENT REPORT 
Ethnic Categories 
Not Hispanic or Latino Hispanic or Latino  
Total Female Male Female Male 
American Indian/Alaska Native 0 0 0 0 0 
Asian 0 1 0 0 1 
Native Hawaiian or Other 
Pacific Islander 0 0 0 0 0 
Black or African American 4 5 1 1 11 
White  14 15 7 10 46 
More Than One Race 0 1 0 1 2 
Total 18 22 8 12 60 
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
46 
  
 
Racial Categories INTERNATIONAL (including Canadian participants) PLANNED 
ENROLLMENT REPORT 
Ethnic Categories 
Not Hispanic or Latino Hispanic or Latino  
Total Female Male Female Male 
American Indian/Alaska Native      
Asian      
Native Hawaiian or Other Pacific Islander     
 
Black or African American      
White       
More Than One Race      
Total     0 
 
 
13.4 Primary Objective, Endpoint(s), Analysis Plan 
  
The primary objective of this trial is to assess the mean perce nt change in duodenal polyp burden (sum 
of diameters from all polyps) from baseline to 6 months post-in tervention for FAP subjects receiving 
weekly erlotinib.  The hypothesis is that weekly erlotinib will  significantly reduce duodenal polyp burden 
after 6 months of treatment.  If  a significant reduction in pol yp burden is shown after 6 months of 
treatment, we will also assess th e grade 2/3 adverse event rate  in this population and compare it to 
historical data.  The hypothesis is that weekly erlotinib will significantly reduce the grade 2/3 AE rate 
compared to historical control data.  The study design below as sesses the co-primary endpoints using a 
hierarchical testing strategy, where the AE primary endpoint wi ll only be assessed if Polyp Burden is 
significantly reduced.  With this design strategy, we’re able t o maintain alpha = 0.05 for each primary 
endpoint.   
 Polyp Burden Prima ry Endpoint:    Based on the prior data from the  FAPEST study, the sulindac/erl otinib 
arm had a 8.5-mm (38%) median decrease (38% decrease for mean as well) in polyp burden compared 
to a median increase of 8 mm (31%) in the placebo arm (44% mean  increase). This di fference was highly 
significant (p<0.001).
20   
 
With 50 evaluable subjects, we would have 93% power to detect a  significant mean percentage 
decrease in polyp burden from baseline of 15% for erlotinib wee kly schedule, with 2-sided significance 
level of 0.05 (1 sample paired t-test).  This assumes an effect  size of 50% and a standard deviation (SD) 
of 30%.  Basically, we could detect ½ a SD for this test, so if the SD ends up being 20%, we could detect a reduction of 10% or more in poly p burden.  For this test, we will assume the user-specified null 
hypothesis is 0%, so that we’re testing any significant reducti on in polyp burden from baseline to 6 
months.  If for some reason, the  sample size doesn’t meet targe t accrual of 50 evaluable subjects, here 
are some other possibilities for the same effect size and alpha .  With at least 34 eligible patients, we’d 
have at least 80% power for the polyp burden primary endpoint.  With at least 35 eligible patients, we’d 
have at least 80% power for both primary endpoints (polyp burde n and AEs), just in case the accrual 
suffers and we need to sto p the trial early.   
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
47 
 Number Eligible Power 
34 80% 
35 81% 
40 86% 
44 90% 
 
AE Primary Endpoint (only tested if Polyp Burden is significant ly reduced, otherwise not 
important):   The combination arm (sulindac and erlotinib daily) from the  FAPEST study, showed much 
higher rates of grade 2/3 AEs (at  least possibly related) compa red to placebo (46% vs. 13%).  It also 
showed much higher rates of Rash for both grade 1-3 (87%) and g rade 2-3 (26%) as compared to 
placebo (20% for grade 1-3 and 0% for grade 2-3).20  Since this study will be testing erlotinib weekly we 
hypothesize that the AE rates w ill be significantly lower than found in the aforementioned Samadder 
study.    
 
With 50 evaluable subjects, we would have 94% power to detect a  reduction in grade 2/3 AE rate from 
50% to 25%, assuming a 2-sided significance level of 0.05.  Thi s is based on an Exact test for a single 
proportion, assuming 50% as the us er specified null hypothesis.   If for some reason , the sample size 
doesn’t meet target accrual of 50 evaluable subjects, here are some other possibilities for the same 
effect size and alpha.  All eligib le participants who start tre atment will be evaluable for the AE primary 
endpoint.   
 
With 44 eligible patients, we’d still have 93% power as well fo r this AE primary endpoint.   With 40 
eligible, we’d have 89% power, a nd with 35 eligible we’d have 8 3% power.  With at least 35 eligible 
patients, we’d have at least 80% power for both primary endpoin ts, just in case the accrual suffers and 
we need to stop the trial early.   
 
Number Eligible Power 
34 78% 
35 83% 
40 89% 
44 93% 
 
13.5 Secondary Objectives, E ndpoints, Analysis Plans 
 
• To evaluate all adverse events associated with the weekly erlotinib; 
• To assess the absolute and percent  change in duodenal polyp num ber from baseline to 6 
months;   
• To assess the absolute and percent changes in lower gastrointes tinal polyp burden and number 
for the subset of participants with ileal pouch anal anastomosi s (IPAA) or ileo-rectal anastomosis 
with rectal stump (anticipated to be approximately 70% of regis tered cohort); and 
• To assess the absolute and percent change in desmoid tumor size  in participants who have 
baseline and follow up CTs performed as part of their standard of care (anticipated to be 
approximately 30% of the registered cohort); 
• Gene expression profiles in duodenal adenomas and uninvolved ti ssue will be compared 
between baseline and endpoint samples using negative binomial s tatistics (DESeq2): 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
48 
 o Identify differentially expressed genes between duodenal polyps  and uninvolved tissue 
at endpoint compared to baseline; 
o Evaluate the effect of weekly erl otinib on EGFR and Wnt target gene expression in 
duodenal adenomas; 
o Evaluate the effect of weekly erlotinib on immune response sign aling in duodenal 
adenomas and uninvolved tissue. 
 
The hypothesis is that weekly erlotinib treatment will reduce t he number of differentially expressed 
genes and EGFR signaling in duode nal adenomas similar to findin gs from the previo us erlotinib + 
sulindac study. We also anticipate Wnt signaling will be inhibi ted in duodenal polyps from patients on 
drug. Using Ingenuity pathway anal ysis (IPA, Qiagen) we will ev aluate the effect of erlotinib on immune 
response signaling pathways (IFNG, IL12) previously observed to  be enhanced in patients receiving 
erlotinib + sulindac.  
 
13.6 Reporting and Exclusions 
 
All registered participants who start treatment and complete bo th the baseline and 6-month post-
baseline evaluation will be evaluable for the polyp burden prim ary endpoint of this study using the 
modified intent-to-treat principle.  We plan to over register b y about 15% to ensure an adequate sample 
size in the primary analysis cohort.  There will be no imputati on for missing data.  A summary and listing 
of all major protocol violation s will be provided.  All details  will be given in the final study report and/or 
manuscript.  Participants lost to  follow-up will be censored on the last date of assessment (or contact) 
and as appropriate for analyses t hat are dependent upon length of study participation.  All eligible 
participants who start treatment will be evaluable for the AE primary endpoint.   
 
13.7 Evaluation of Toxici ty (Secondary endpoint) 
 All registered and treated part icipants will be evaluable for a dverse events (AEs) from the time of their 
first dose of weekly erlotinib treatment.  To evaluate the AE p rofile for this treatment, the maximum 
grade for each type of adverse event will be recorded for each participant and fre quency tables will be 
reviewed to determine the overa ll patterns. The number and seve rity of adverse events will be 
tabulated and summarized across a ll grades.  Grade 2+ adverse e vents will be similarly described and 
summarized separately.  As per NCI CTC Vers ion 4.0, toxicities are defined as adverse events that are 
classified as either possibly, probably, or definitely related to the interventional agent.  Overall toxicity 
incidence, as well as toxicity profiles will be explored and summarized. Frequency distributions, graphical techniques, and other descriptive measures will form the basis of these analyses. In addition, 
we will review all adverse event data that are graded as 3, 4, or 5 and classified as either “unrelated or 
unlikely to be related” to the study intervention in the event of an actual relationship developing. 
 
13.7.1 Adverse Event Stopping Rule 
 
The trial will be monitored clos ely for occurrence of adverse e vents by the study team and by the Mayo 
Clinic Cancer Center Data Safety and Monitoring Board (DSMB) us ing the adverse event (AE) stopping 
rule specified below.   
 
Adverse Event Stopping Rule: The stopping rule specified below is based on the knowledge available at 
study development. We note that t he Adverse Event Stopping Rule  may be adjusted in the event of 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
49 
 either (1) the study re-opening to accrual after any temporary suspension or (2) at  any time during the 
conduct of the trial and in consideration of newly acquired inf ormation regarding the adverse event 
profile of the treatment(s) under investigation. The study team in consultation with the Mayo DSMB 
may also choose to suspend accrual because of unexpected advers e event profiles that have not crossed 
the specified rule below. 
 
Accrual will be temporarily suspe nded to this study if at any time we observe events considered at least 
possibly related to study treatme nt (i.e., an adv erse event wit h attribute specified as "possible", 
"probable", or "definite") that  satisfy any of the following cr iteria: 
 
• If, at any time, two of the init ial 20 treated participants or 10% of all participants, i.e. when 
accrual is greater than 20 partic ipants, have experienced a Grade 4 adverse event  
• If, at any time, a Grade 5 event  occurs that is at least possib ly related to treatment  
• In addition, each Grade 5 event, regardless of attribution, wil l be reviewed on a case-by-case 
basis in a real-time fashion to determine whether or not study accrual should be suspended. We 
also will review all Grade 4 adverse events, regardless of attr ibution, to monitor the emergence 
of any previously unrecognized tr eatment-related adverse events .  
 
13.8 Evaluation of Response 
 
All registered participants who start treatment and complete bo th the baseline and 6-month post-
baseline evaluation will be evaluable for the polyp burden prim ary endpoint of this study using the 
modified intent-to-treat principle.  All conclusions regarding efficacy will be based on all participants 
who completed both the baseline and 6-month post -baseline evaluations.  Sub-analyses may be 
performed on the subsets of parti cipants, excluding those for whom major protocol deviations have 
been identified (e.g., early death due to other reasons, early discontinuation of intervention, major 
protocol violations, etc.).  How ever, sub-analyses may not serv e as the basis for drawing conclusions 
concerning efficacy, and the rea sons for excluding participants  from the analysis should be clearly 
reported.  For all measurements of response (i.e. the polyp bur den primary endpoint), the 95% 
confidence intervals will also be provided.  All eligible patie nts who start treatment will be evaluable for 
the AE primary endpoint.   
 
13.9 Interim Analysis 
 Not applicable for this study.    
13.10 Ancillary Studies 
 Laboratory measures will be corre lated with participant outcome s (i.e., polyp burden, adverse events) 
and with each other as well.  Cut-points will be determined based on previously def ined and accepted 
standards.   Descriptive statistics and simpl e scatter plots will be generat ed to review the tissue-based 
biomarker data .  For continuous variables, the actual and % change in the leve l of each of the 
biomarkers from pre- to post-intervention will be explored using Wilcoxon signed rank tests, and paired sample t-tests.  All categorical variables will be analyzed usi ng chi-square tests or Fisher’s exact test.  For 
all translational endpoints, any  notable statistical result wil l be viewed as an impetus for further study 
rather than as a definitive finding in and of itself.  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
50 
 14. ETHICAL AND REGULATORY CONSIDERATIONS 
 
14.1 Form FDA 1572 
 
Prior to initiating this study, the Protocol Lead Investigator at the Lead or Participating Organization(s) 
will provide a signed Form FDA 1572 stating that the study will  be conducted in compliance with 
regulations for clinical investigations and listing the investi gators, at each site that will participate in the 
protocol. All personnel directly involved in the performance of  procedures required by the protocol and 
the collection of data should  be listed on Form FDA 1572. 
 
14.2 Other Required Documents 
 
14.2.1 Current (within two years) CV or biosketch for all study  personnel listed on the Form FDA 1572 
and Delegation of Tasks form for the Lead Organization and all Participating Organizations.  
 
14.2.2 Current medical licenses (where applicable) for all stud y personnel listed on Form FDA 1572 and 
Delegation of Tasks form for the  Lead Organization and all Participating Organizations. 
 
14.2.3  Lab certification ( e.g., CLIA, CAP) and lab normal ran ges for all labs listed on Form  FDA 1572 for 
the Lead Organization and all Participating Organizations. 
 14.2.4  Documentation of training in Good  Clinical Practice for all stu dy personnel listed on the FDA 
Form 1572 and Delegation of Tasks form for the Lead Organizatio n and all Participating Organizations. 
 
14.2.5  Documentation of Federalwide Assurance (FWA) number for the Lea d Organization and all 
Participating Organizations. 
 14.2.6  Signed Investigator’s Brochure/Package Insert acknowledgement f orm 
 
14.2.7  Delegation of Tasks form for the  Lead Organization and all Participating Organizations signed by 
the Principal Investigator for e ach site and initialed by all s tudy personnel listed on the form 
 
14.2.8  Signed and dated NCI, DCP Financial Disclosure Form for all study personnel listed on Form FDA 
1572 for the Lead Organization and all Participating Organizati ons 
 
14.3 Central Institutional Review Board Approval 
 Prior to initiating the study and receiving agent, the Investig ators at the Lead Organization and the 
Participating Organization(s) mu st obtain written approval to conduct the study from the appropriate 
CIRB. Should changes to the study  become necessary, protocol am endments will be submitted to the 
DCP PIO according to DCP Amendme nt Guidelines. The DCP-approved  amended protocol must be 
approved by the IRB pr ior to implementation 
 
14.4 Informed Consent 
 All potential study participants will be given a copy of the IRB-approved Informed Consent to review. 
The investigator will explain all aspects of the study in lay l anguage and answer all questions regarding 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
51 
 the study. If the participant decides to participate in the stu dy, he/she will be asked to sign and date the 
Informed Consent document. The study agent(s) will not be relea sed to a participant who has not signed 
the Informed Consent document. S ubjects who refuse to participa te or who withdraw from the study 
will be treated without prejudice. 
 
Participants must be provided th e option to allow the use of bl ood specimens, other body fluids, and 
tissues obtained during testing, o perative procedures, or other  standard medical practices for further 
research purposes. If applicable , statement of t his option may be included within the informed consent 
document or may be provided as a n addendum to the consent. A Mo del Consent Form for Use of Tissue 
for Research is available through a link in the DCP website.  
Prior to study initiation, the i nformed consent document must b e reviewed and approved by NCI, DCP, 
the Consortium Lead Organization , and the IRB at each Organizat ion at which the protocol will be 
implemented. Any subsequent change s to the informed consent mus t be approved by NCI, DCP, the 
Consortium Lead Organization’s I RB, and then submitted to each organization’s IRB for approval prior to 
initiation.  
14.5 Submission of Regulatory Documents 
 All regulatory documents are collected by the Consortia Lead Or ganization and reviewed for 
completeness and accuracy. Once the Consortia Lead Organization  has received complete and accurate 
documents from a participating organization, the Consortium Lea d Organization will forward the 
regulatory documents to DCP’s Regulatory Contractor:   Paper Document/CD-ROM Submissions: 
 Regulatory Affairs Department 
 CCS Associates, Inc. 
 2001 Gateway Place, Suite 350 West  San Jose, CA 95110  Phone: 650-691-4400  Fax: 650-691-4410 
 
 E-mail Submissions: 
 regulatory@ccsainc.com  
 Regulatory documents that do not require an original signature may be sent electronically to the 
Consortium Lead Organization for review, which will then be ele ctronically forwarded to DCP’s 
Regulatory Contractor.  
14.6 Other 
 This trial will be conducted in compliance with the protocol, G ood Clinical Practice (GCP), and the 
applicable regulatory requirements.     
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
52 
 15. FINANCING, EXPENSES, AND/OR INSURANCE 
 
No expenses will be incurred by t he study participants and/or t heir insurance carriers.  This does not 
include costs of tests and proce dures that are a part of the pa rticipant’s normal clin ical care.  This also 
does not include any injuries or illnesses the participant may have related to their participation on the 
study.  In the event of an inju ry or illness, the study partici pant and/or their insurance carrier will be 
responsible for all expenses rel ated to the injury or illness.  Participants may be provided remuneration 
for their participation in the s tudy, at the discretion of the local Institutional Review Board.  
 
REFERENCES 
 1. Giardiello FM, Hamilton SR, Kru sh AJ, Piantadosi S, Hylind L M, Celano P, Booker SV, Robinson CR, 
Offerhaus GJ. Treatment of colonic and rectal adenomas with sul indac in familial adenomatous 
polyposis. The New England jo urnal of medicine 1993;328:1313-6.  
2. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Tr imbath JD, Piantadosi S, Garrett E, 
Geiman DE, Hubbard W, Offerhaus GJ, Hamilton SR. Primary chemoprevention of familial adenomatous polyposis with suli ndac. The New England journal of  medicine 2002;346:1054-9. 
3. Debinski HS, Trojan J, Nugent KP, Spigelman AD, Phillips RK.  Effect of sulindac on small polyps in 
familial adenomatous polypo sis. Lancet 1995;345:855-6. 
4. Nugent KP, Farmer KC, Spigel man AD, Williams CB, Phillips RK . Randomized controlled trial of 
the effect of sulindac on duodena l and rectal polyposis and cel l proliferation in patients with 
familial adenomatous polyposis. T he British journal of surgery 1993;80:1618-9. 
5. Phillips RK, Wallace MH, Lynch  PM, Hawk E, Gordon GB, Saunde rs BP, Wakabayashi N, Shen Y, 
Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G. A randomised, double blind, placebo  controlled study of celecoxib , a selective cyclooxygenase 2 
inhibitor, on duodenal polyposis in familial adenomatous polypo sis. Gut 2002;50:857-60. 
6. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavora l M, Lechuga MJ, Ger letti P, Tang J, 
Rosenstein RB, Macdonald K, Bhad ra P, Fowler R, Wittes J, Zaube r AG, Solomon SD, Levin B. 
Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of 
medicine 2006;355:885-95. 
7. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gord on GB, Wakabayashi N, Saunders 
B, Shen Y, Fujimura T, Su LK, Levin B, Godio L, Patterson S, Ro driguez-Bigas MA, Jester SL, King 
KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmer man S, Sherman JW, Kelloff 
G. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in fa milial adenomatous polyposis. The 
New England journal of medicine 2000;342:1946-52. 
8. M N. Pfizer, Inc.; Withdrawal  of Approval of Familial Adenom atous Polyposis Indication for 
CELEBREX. In: Register OotF, e d. Volume 2015. New York, NY: P, 2012. 
9. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, 
DuBois RN, Jetton TL, Morrow JD. Epidermal growth factor recept or activation induces nuclear 
targeting of cyclooxygenase-2, basolateral release of prostagla ndins, and mitogenesis in 
polarizing colon cancer cells. Pr oceedings of the National Acad emy of Sciences of the United 
States of America 1997;94:657-62. 
10. Eisinger AL, Nadauld LD, Shelton DN, Peterson PW, Phelps RA , Chidester S, Stafforini DM, 
Prescott SM, Jones DA. The adenom atous polyposis coli tumor sup pressor gene regulates 
expression of cyclooxygenase-2 by  a mechanism that involves retinoic acid. The Journal of 
biological chemistry 2006;281:20474-82. 
11. Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coff ey RJ, Threadgill DW. Importance of 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
53 
 epidermal growth factor receptor signaling in establishment of adenomas and maintenance of 
carcinomas during intestinal tum origenesis. Proceedings of the National Academy of Sciences of 
the United States of America 2002;99:1521-6. 
12. Jasperson KW, Tuohy TM, Nekla son DW, Burt RW. Hereditary an d familial colon cancer. 
Gastroenterology 2010;138:2044-58. 
13. Biasco G, Pantaleo MA, Di Febo G, Calabrese C, Brandi G, Bu low S. Risk of duodenal cancer in 
patients with familial adenomatous polyposis. Gut 2004;53:1547;  author reply 1547. 
14. Bulow S, Bjork J, Christensen IJ, Fausa O, Jarvinen H, Moes gaard F, Vasen HF. Duodenal 
adenomatosis in familial adenom atous polyposis. Gut 2004;53:381 -6. 
15. Offerhaus GJ, Giardiello FM, Krush AJ, Booker SV, Tersmette  AC, Kelley NC, Hamilton SR. The risk 
of upper gastrointestinal cancer in familial adenomatous polypo sis. Gastroenterology 
1992;102:1980-2. 
16. Jagelman DG, DeCosse JJ, Busse y HJ. Upper gastrointestinal cancer in familial adenomatous 
polyposis. Lancet 1988;1:1149-51. 
17. Vasen HF, Bulow S, Myrhoj T, Mathus-Vliegen L, Griffioen G,  Buskens E, Taal BG, Nagengast F, 
Slors JF, de Ruiter P. Decision analysis in the management of d uodenal adenomatosis in familial 
adenomatous polyposis. Gut 1997;40:716-9. 
18. Heiskanen I, Kellokumpu I, Jar vinen H. Management of duodenal adenomas in 98 patients with 
familial adenomatous polypo sis. Endoscopy 1999;31:412-6. 
19. Conio M, Gostout CJ. Management of duodenal adenomas in 98 patients with familial 
adenomatous polyposis. Gastroi ntestinal endoscopy 2001;53:265-6 . 
20. Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Sa mowitz W, Jones D, Tavtigian SV, 
Done MW, Berry T, Jasperson K, P appas L, Smith L, Sample D, Dav is R, Topham MK, Lynch P, 
Strait E, McKinnon W, Burt RW, Kuwada SK. Effect of Sulindac an d Erlotinib vs Placebo on 
Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial. JAMA 
2016;315:1266-75. 
21. Saba NF, Hurwitz SJ, Kono SA,  Yang CS, Zhao Y, Chen Z, Sica  G, Muller S, Moreno-Williams R, 
Lewis M, Grist W, Chen AY, Moore CE, Owonikoko TK, Ramalingam S , Beitler JJ, Nannapaneni S, 
Shin HJ, Grandis JR, Khuri FR, C hen ZG, Shin DM. Chemopreventio n of head and neck cancer with 
celecoxib and erlotinib: results  of a phase ib and pharmacokinetic study. Cancer prevention 
research 2014;7:283-91. 
22. Lubet RA, Szabo E, Iwata KK, Gill SC, Tucker C, Bode A, Ste ele VE, Juliana MM, Nicastro HL, 
Grubbs CJ. Effect of intermittent  dosing regimens of erlotinib on methylnitrosourea-induced 
mammary carcinogenesis. Cancer prevention research 2013;6:448-5 4. 
23. Milton DT, Azzoli CG, Heelan RT, Venkatraman E, Gomez JE, K ris MG, Krug LM, Pao W, Rizvi NA, 
Dunne M, Miller VA. A phase I/II study of weekly high-dose erlo tinib in previously treated 
patients with nonsmall cell lung cancer. Cancer 2006;107:1034-4 1. 
24. Grommes C, Oxnard GR, Kris M G, Miller VA, Pao W, Holodny AI , Clarke JL, Lassman AB. 
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung 
cancer. Neuro-oncology 2011;13:1364-9. 
25. Hyman N, Waye JD. Endoscopic four quadrant tattoo for the i dentification of colonic lesions at 
surgery. Gastrointestina l endoscopy 1991;37:56-8. 
26. Shatz BA, Thavorides V. Colonic tattoo for follow-up of end oscopic sessile polypectomy. 
Gastrointestinal endoscopy 1991;37:59-60. 
 
  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
54 
  
Summary of Changes – Informed Consent Form  
 
NCI Protocol #:  MAY2016-07-01 
Local Protocol #: MAY2016-07-01 Protocol Version Date:  July 22, 2019  Protocol Title:   Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden 
Associated with Familial Adenomatous Polyposis  Informed Consent Versio n Date:  July 22, 2019  
 Please note that the page numbers in the table below refer to the Word version of the Informed Consent Form that w ill be submitted to the CIRB. 
 
 
There are no changes in the informed consent template other tha n the version number and date. 
  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
55 
  
NCI, DCP CONSENT FORM TEMPLATE FOR CONSORTIA CANCER 
CHEMOPREVENTION TRIALS 
 
Study Title for Study Participant s:  Testing Weekly Erlotinib f or Familial 
Adenomatous Polyposis (FAP) 
 
Official Study Title for Interne t Search on http://www.Clinical Trials.gov: Phase II 
Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burde n Associated 
with Familial Adenomatous Polyposis 
 Introduction  
 
This is a clinical trial, a type  of research study. Your study doctor will explain the clinical trial to 
you. Clinical trials include only people who choose to take par t in the research. Please take your 
time to make your decision abo ut volunteering. You may discuss your decision with your friends 
and family. You can also discuss this study with your health care team. If you have any 
questions, you can ask your study  doctor for more of an explana tion. You should only agree to 
participate in this study when you are comfortable enough with the information so that you can 
make an informed decision about joining.  
 
What is the usual approach to my Familial Adenomatous Polyposis  (FAP)?   
 
You are being asked to take part in this study because you have  FAP and are at increased risk 
for developing colon cancer. Peo ple who are at increased risk a nd choose not to participate in a 
study are usually followed closel y by their doctor, with regular examinations of their colon, 
rectum, and small bowel to watch  for the development of polyps and cancer.  
 
What are my other choices if I do not take part in this study?  
 
If you decide not to take part in this study, you have other ch oices. For example: 
• you may choose to have the usua l approach described above, 
• you may choose to take part in a different study, if one is available,  
• or you may choose to do nothing. 
 
Why is this study being done? 
 
The purpose of this study is to test the safety of erlotinib (T arceva®) taken once per week and 
find out what effects, if any, erlotinib has on people and thei r risk of colon cancer. There will be 
about 60 people taking part in this study.  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
56 
  
Erlotinib (Tarceva®) is a targete d cancer therapy drug that int erferes with the growth and 
spread of cancer cells in the bo dy.  Targeted cancer therapies “target” cancer cells while doing 
little damage to normal cells.  Erlotinib has been effective in  treating many different kinds of 
cancer, including lung and pancr eatic cancer, and is approved b y the FDA for targeted cancer 
therapy.  It is not approved for cancer prevention.   Several recent studies have shown that erlotinib may also be ef fective in reducing the number 
of polyps and increasing the time  to reappearance of polyps.  This study will test a weekly dose 
of erlotinib, instead of a daily dose, to see if it works just as well with fewer worrisome side 
effects.  Because Erlotinib has n ot been approved for reduction  of polyps, using it for this study 
is experimental.  Everyone participating in the study will be given the same dose  of erlotinib, which will be 350 
mg (two 150 mg tablets plus two 25 mg tablets) once every week for 6 months.   
 
How long will I be in this study? 
 
You will be on the study for up to  8 months. After signing this informed consent document, you 
will have several tests to find out if you can take the study d rug.  This may take up to 28 days 
before you begin taking the study drug. You will receive the st udy drug for 6 months.  Even if 
you do not finish the study, your  doctor will continue to watch  you for side effects and follow 
your condition for one additional month.  
 
What extra tests and procedures will I have if I take part in t his study? 
 Before you begin the study: 
You will sign this document, and you will be “pre-registered” a nd assigned your unique 
participant identification (PID) number.  From that point forward, all of your information and 
specimens will be identified only with this number. Some of the  exams, tests, and procedures 
you will have are part of the u sual approach for your condition . However, there are some extra 
examinations, blood tests, and procedures that you will need to have if you take part in this study.  
 
You will need to have the following extra evaluations and proce dures  to find out if you can be in 
the study:  
• We will review your medical and surgical history. 
• We will review of any medications you are taking and any sympto ms you are experiencing. 
• Blood and urine will be collected for tests to check your healt h and how well your organs 
function. 
• Assessment of your alcohol and tobacco use 
• Optional:  Blood and urine will be collected for research. 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
57 
 • A pregnancy test will be performed within 7 days prior to regis tration if you are capable of 
having children. 
• Esophagogastroduodenoscopy (EGD) and lower gastrointestinal end oscopy procedures will 
be performed to look at your digestive system and evaluate any polyps that are present 
• Biopsies of your digestive tract will be collected for research  
• If you have been diagnosed with desmoid tumors and have CT (com puted tomography) 
imaging at least twice yearly a s part of your standard clinical  care, copies of the CT images 
and the written reports will be collected. 
 
During the biopsy procedures, sm all pieces of tissue are removed in a similar way to biopsies 
done for diagnosis.  These will be tested and compared to piece s of tissue collected at the end 
of the study. We are looking for any changes that might have been caused by the study drug. 
 If all of the exams, tests, and procedures show that you can ta ke part in the study, and you 
choose to, then you will be provided with: 
• Study drug 
• A diary to record the study drug you’ve taken and any symptoms or side effects that you 
might experience  
• Instructions for taking the study drug and completing the diary    
• Prescriptions for medications, such as skin cream and antibioti cs, to take if needed to help 
relieve any of the expected symptoms, if they occur.  
 
During the study: 
During the study, you will take erlotinib once week, on the sam e day and approximately the 
same time each week.  You should t ake the erlotinib at least on e hour before or two hours after 
eating any food.  You will be re quired to keep a diary that not es taking this medication and any 
other medications you take.  As part of this study you will also be asked to answer question s about your tobacco and alcohol 
use, both before you begin the study and again at the Month 6 v isit.  Researchers want to see if 
tobacco and alcohol use affects t he side effects people might get while on this study, or if 
tobacco and alcohol use modifies the effects of the study agents.  Month 1:  You will return for a v isit, physical exam, review of your medication diary, review of 
any symptoms you are experiencin g and any medications you are t aking.  Blood and urine will 
be collected to check fo r safety and toxicity. 
 Approximately Months 2, 4, and 5:  You will receive a phone call from the study team to see 
how you are doing.  You will be a sked about any symptoms you ar e experiencing and any 
medications you are taking.  Month 3:  You will return for a v isit, physical exam, review of your medication diary, review of 
any symptoms you are experiencin g and any medications you are t aking.  Your left over study 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
58 
 drug will be collected, and you will be provided with a new supply.  Blood and urine will be 
collected to check for safety and toxicity. Additional optional  blood and urine will be collected 
for research.  A pregnancy test will be performed if you are a woman capable of having 
children.  Month 6 (of if you discontinue p articipation in the study early for any reason):   You will return 
for a visit, physical exam, review of your medication diary, review of any symptoms you are experiencing and any medications you are taking.  You will be a sked to complete follow-up 
assessments of your alcohol and tobacco use, which will take ab out 10 minutes.  Your 
medication diaries and left ove r study drug will be collected.  Optional blood and urine will be 
collected for research. Blood and urine will be collected to ch eck for safety and toxicity.  A 
pregnancy test will be performed if you are a woman capable of having children. You will also 
have another EGD, endoscopy, and biopsy collection to look at y our digestive system and 
evaluate any polyps that are present.  You will be asked to com plete a short questionnaire 
about your experience on this study (Was It Worth It?), which s hould take less than 5 minutes. 
 
If you have been diagnosed with desmoid tumors and have CT (com puted tomography) imaging 
at least twice yearly as part of your standard clinical care, c opies of the CT images and the 
written reports will be collected. 
 Approximately Month 7:  You will be asked about any symptoms yo u are experiencing and any 
medications you are taking.  If a ny of the lab tests done at Mo nth 6 were abnormal, they will be 
repeated at this visit.  This vis it may be done by telephone if  there were no abnormal lab test 
results. 
 
A study calendar is attached to this document that shows when t hese tests and procedures will 
take place.  
 
What possible risks can I expect from taking part in this study ?  
If you choose to take part in the study, there is a risk that y ou may: 
• Lose time at work or home and spend more time in the hospital or doctor’s office than 
usual 
• Be asked sensitive or private que stions which you normally do n ot discuss, for example 
about your tobacco and alcohol use 
• There can also be a risk in finding out new genetic information  about you. New health 
information about inherited traits that might affect you or blo od relatives could be 
found during a study. 
 The erlotinib used in this study  may affect how different parts  of your body work, such as your 
liver, kidneys, heart, and blood . The study doctor will be testing your blood and urine and will 
let you know if changes occur th at may affect your health.  There is also a risk that you could 
have side effects.  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
59 
 Here are important poi nts about side effects: 
• The study doctors do not know w ho will or will not have side effects. 
• Some side effects may go away soon , some may last a long time, or some may never go 
away.  
• Some side effects may interfere w ith your ability to have child ren. 
• Some side effects may be serious a nd may even result in death.  
 
Here are important points about  how you and the study doctor ca n make side effects less of a 
problem: 
• Tell the study doctor if you not ice or feel anything different so they can see if you are 
having a side effect. 
• The study doctor may be able to treat some side effects. 
• The study doctor may adjust the  study drugs to try to reduce si de effects. 
 The tables below show the most common side effects that we know  about erlotinib, some of 
which may be serious. There might be other side effects that we do not yet know about. If important new side effects are f ound, the study doctor will dis cuss these with you. 
 
Possible Side Effects of erlotinib 
COMMON, SOME MAY BE SERIOUS  
In 100 people receiving erlotinib, more than 20 may have: 
• Red and bumpy skin that may itch (Rash) 
• Loose stool (Diarrhea) 
• Decreased appetite or not feeling hungry (Anorexia) 
• Difficulty breathing or shortness of breath (Dsypnea) 
• Cough 
• Feeling sick to your stomach (Nausea)  
• Infection 
• Throwing up (Vomiting) 
• Tiredness or fatigue 
 
 
  
 
    
 
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
60 
 OCCASIONAL, SOME MAY BE SERIOUS  
In 100 people receiving erloti nib, from 4 to 20 may have:  
• Sores in the mouth (oral mucositis) 
• Itching 
• Acne 
• Dry skin 
• Weight loss 
• Irritation (redness, swelling, warmth, and pain) or infection o f the skin around 
fingernails or toenails 
• Eye infection/pink eye 
• Dry eyes 
• Stomach pain or pain in the abdomen (belly) 
• Red bumps on the skin that are red, sore, and possibly infected  
 
 
     
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
61 
  
 
RARE, SOME MAY BE SERIOUS  
In 100 people receiving erlo tinib, 3 or fewer may have:  
Although very rare, some of the side effects listed below can c ause death. 
• Abnormal laboratory result whi ch may indicate liver damage 
• Liver damage 
• Kidney damage which may cause sw elling, may require dialysis 
• Swelling, irritation, or scarring of the lungs, which may cause  pain or difficulty 
breathing 
• A tear or hole in the stomach that may require surgery. More co mmon in people 
with ulcers (sores in the stomac h), diverticulitis (redness, pa in, and swelling of part of 
the belly), and in people who ta ke some types of drugs (NSAIDS,  corticosteroids, 
chemotherapy). Talk to your study  doctor about drugs to avoid. 
• Severe blistering or peeling of the skin 
• Patches of skin may become darker in color 
• Redness, swelling, sores, or a te ar or hole in the eye which ma y cause pain or blurred 
vision 
• Increased bleeding (internal bleeding, nose bleed). More common  in people who 
take blood thinning drugs. 
• Increased body hair growth, hair loss, eyelash/eyebrow changes,  or brittle/loose 
fingernails or toenails 
• Severe diarrhea or vomiting can cause an imbalance of minerals in the blood (called 
electrolytes) such as low potassi um, with symptoms that may include weakness, 
fatigue, muscle cramps, or constipation 
• In people with cancer of the pan creas who took combined treatment of erlotinib plus 
gemcitabine: heart attack, stroke, fever, decreased red blood c ells (anemia), which 
may cause tiredness or may require  blood transfusion, and decre ased platelets which 
may cause easy bleeding, or longer bleeding.  
 
    
 
      
 
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
62 
  
 
 
POSSIBLE, SOME MAY BE SERIOUS  
The frequency of some individual  side effects has not yet been determined:  
• Shoulder pain 
• Change in urine color 
• Indigestion 
• Gas in the belly, burping 
• Irritability (easily annoyed or made angry) 
• Swelling of the face, hands, feet, or ankles 
• Runny nose 
• Dizziness 
• Headache 
• Blood clot in the lung which may  cause pain, shortness of breat h 
• Stroke (stoppage of blood flow t o your brain which may cause pa ralysis, weakness, 
headache) 
• Death or injury to unborn baby 
• Because of the potential harm to  the infant, women should be ad vised against breast-
feeding while receiving erlotinib therapy  
 
Risks of the blood draw : You may have pain, bruising, a blood clot, or rarely, an infe ction at the 
site of the needle stick.  You may be asked to avoid donating b lood during and for one month 
after you stop taking a study drug.  
Risks of the EGD/Lower endoscopy with biopsies :  There is a very small risk that the scope may 
cause a hole in the wall of your throat or stomach.  If that we re to happen, the doctor will 
arrange for surgery to repair it .  There is a very small risk of bleeding related to the biopsy. 
 
There is a small risk that you will have a reaction to the drugs that are given to make you more comfortable during the EGD procedure.  You may have slowed breathing, a slowed heart rate, or you may feel sick to your stom ach as the drugs wear off. 
 
You should not drive, sign legal documents, or perform other si milar activities for 24 hours after 
the procedure. You will need to a rrange for someone to drive yo u home after the EGD 
procedures. 
 
Reproductive risks:  You should not get pregnant, breastfeed, or father a baby whil e in this 
study and for at least 14 days a fter stopping the study drug. T he study drug, erlotinib, used in 
this study could be very damagin g to an unborn baby. Check with  the study doctor about what 
types of birth control, or pregnancy prevention, to use while i n this study.  
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
63 
 Foods, medications, and activities that should be avoided durin g the study: There are a few 
foods, medications, and activities that may have an impact on t he effectiveness of the study 
drug. 
• While participating in the study, you should avoid grapefruit-c ontaining products such 
as grapefruits, grapefruit juice, and any sodas that contain gr apefruit juice (Fresca® and 
Squirt®). 
• While participating in the study, you must not smoke or use any  tobacco products.  
Urine tests will be done to check  your exposure to tobacco and tobacco smoke.  
Smoking interferes with the way erlotinib works. 
• While participating in the study, you must not take more than 8 1 mg aspirin (1 baby 
aspirin) per day or more than 650 (two adults-sized tablets) pe r week. 
• While participating in the study, you must not take medications  that change the acidity 
of your digestive tract, such a s Protocol Pump Inhibitors (PPIs ) for gastric reflux.  If you 
have a prescription for a PPI, and your doctor believes it is s afe, an alternative 
medication can be suggested.   H owever, you will still have to skip this medication on 
the day before and the day of your erlotinib dose. 
• While participating in the study, you must be sure to inform th e study team of any new 
medications, including over-the-counter medications, prescripti on drugs, and dietary 
supplements. 
 
What possible benefits can I expect from taking part in this st udy?  
 
This study may or may not help you because we do not know how t he study drugs will compare 
to the usual approach for your condition. This study may help u s learn things that could help 
people in the future. 
 
Can I stop taking part in this study?  
 Yes. You can decide to stop at any time. If you decide to stop for any reason, it is important to let the study doctor know as soon  as possible so you can stop s afely. If you stop, you can decide 
whether or not to let the study doctor continue to provide your  medical information to the 
organization running the study.  
 For the tobacco and alcohol use questions, you can decide to no t answer some or all of the 
questions. Your decision will not affect whether you can partic ipate in the study, and it will not 
affect your relationship with your doctor or the study staff.  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
64 
 The study doctor will tell you about any new information or cha nges in the study that could 
affect your health or your willingness to continue in the study . 
 
The study doctor may take you out of the study: 
• If your health changes.  
• If the study is no longer in your best interest. 
• If new information becomes available. 
• If you do not follow the study rules. 
• If the study is stopped early for any reason by the sponsor, IR B or FDA. 
 
What are my rights in this study?  
Taking part in this study is your choice. No matter what decision you make, and even if your 
decision changes, there will be n o penalty to you. You will not  lose medical care or any legal 
rights. 
 For questions about your rights w hile in this study, call the I nstitutional Review Board at  
<telephone number> . 
 
 
What are the costs of taking part in this study?  
 
The erlotinib will be supplied at no charge while you take part  in this study. The cost of study-
specific biopsies and exams, tests , and any other procedures wi ll be paid for by the study. 
 
Some costs associated with your care may be considered standard  of care, and will be billed to 
you or your insurance company. Y ou will have to pay for any cos ts (including deductibles and 
co-payments) not covered b y your health insurer. 
 
The study will pay for the following:  
• Erlotinib 
• Medications to help mana ge common side effects 
• Physical exams 
• Blood and urine tests 
• Blood and urine collection for optional research 
• Pregnancy tests, if applicable 
• EGD and/or lower GI Endoscopy exams that do not occur at time p oints that are the 
same as your usual and routine clinical care 
• Questionnaires and medication diaries 
• Phone calls to check on side effects and symptoms 
 
You or your insurance company  will pay for the following: 
• Medications needed to manage unc ommon or severe side effects, if they occur 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
65 
 • EGD and/or lower GI Endoscopy exams, if they are completed at a  time point that is the 
same as your usual and routine clinical care 
 
Before you decide to be in the st udy, you should check with your health plan or insurance 
company to find out exactl y what they will pay for.  
 
Will I be paid for participating in this study? 
 
You will not be paid for participating in this study.  However,  at the end of your study 
participation, you may receive a  payment of up to $400 to help cover expenses related to study 
participation.  If you complete only part of the study, you wil l receive part of this total payment.  
For example, if you complete hal f (3 months) of the study, you would receive half of the total 
payment. 
  
What happens if I am injured or hurt because I took part in thi s study?  
 
If you feel you have been injured or hurt as a result of taking  part in the study, it is important 
that you tell the study doctor immediately. You will get medica l treatment if you are injured or 
hurt as a result of taking part in this study.   The study sponsors will not offer to pay for medical treatment for injury. Your insurance 
company may not be willing to pay for study-related injury. If you have no insurance coverage, 
you would be responsible for any  costs. Even though you are in a study, you keep all of your 
legal rights to receive payment for injury caused by medical errors.
 
 
Who will see my medical information?  
 Your privacy is very important to us.  The study doctors will make every effort to protect it.  The 
study doctors have a privacy permit to help protect your records if there is a court case.  However, some of your medical inf ormation may be given out if r equired by law.  If this should 
happen, the study doctors will do t heir best to make sure that any information that goes out to 
others will not identify who you are.   Some of your health information, such as your response to cance r treatment, results of study 
tests, and medicines you took, will be kept by the study sponso r in a central research database.  
However, your name and contact information will not be put in t he database.  If information 
from this study is published or pre sented at scientific meeting s, your name and other personal 
information will not be used.   There are organizations that m ay look at your study records.  Y our health information in the 
research database also may be sh ared with these organizations.  They must keep your 
information private, unless requi red by law to give it to anoth er group.   
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
66 
 There are organizations that may  inspect your records. These or ganizations are required to 
make sure your information is kept private. Some of these organ izations are: 
• The study sponsor, National Cancer  Institute, Division of Cance r Prevention  
• The Central Institutional Review  Board, CIRB, is a group of peo ple who review the 
research with the goal of protecting the people who take part i n the study. 
• The Food and Drug Administration and the National Cancer Institute in the US, and 
similar organizations if other countries are involved in the st udy. 
• The National Cancer Institute will obtain information for this clinical trial under data 
collection authority Title 42 U.S.C. 285. 
 
Where can I get more information?  
 
You may visit the NCI Web site at http://cancer.gov/  for more information about studies or 
general information about cancer . You may also call the NCI Cancer Information Service to get 
the same information at: 1-800 -4-CANCER (1-800-422-6237).  
 
A description of this clinical trial will be available on http://www.clinicaltrials.gov  as required by 
U.S. law. This Web site will not include information that can i dentify you. At most, the Web site 
will include a summary of the results. You can search this Web site at any time. 
 
Who can answer my questions about this study?  
You can talk to the <name>,  at <telephone number>  about any questions or concerns you have 
about this study or to report side effects or injuries.  
 
 
This section is about optional studies you can choose to take p art in.  
This part of the consent form i s about optional studies that yo u can choose to take part in. You 
will not get health benefits from any of these studies. The res earchers leading this optional 
study hope the results will help other people with cancer in th e future. 
 
The results will not be added to y our medical records, and you or your study doctor may not 
know the results. You will not be billed for these optional stu dies.  
 You can still take part in the mai n study even if you say ‘no’ to any or all of these studies. If you 
sign up for but cannot complete a ny of the studies for any reason, you can still take part in the 
main study. 
 
 
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
67 
 Optional Specimen Collections fo r Laboratory Studies and/or Bio banking for 
Possible Future Studies  
 
Researchers are trying to learn more about cancer and other hea lth problems. Much of this 
research is done using specimens from your biopsies, blood, and  urine. Through these studies, 
researchers hope to find new ways to prevent, detect, treat, or  cure health problems.  
 
Some of these studies may be abou t genes. Genes carry informati on about features that are 
found in you and in people who ar e related to you. Researchers are interested in the way that 
genes affect how your body  responds to treatment. 
 
If you choose to take part, your  blood, your urine, and specimens of your tissue will be 
collected. The researchers ask you r permission to store and use  your specimens and health 
information for medical research. The research that may be done  is unknown at this time. 
Storing specimens for future st udies is called “biobanking”. Th e Biobank is being run by the 
Cancer Prevention Network (CPN) at the Mayo Clinic and supporte d by the National Cancer 
Institute. 
 
WHAT IS INVOLVED?  
 
If you agree to take part, here is what will happen next: 
• About 20 milliliters of blood will be collected from a vein in your arm. 
• A specimen of your urine will be collected. 
• Any tissue specimens collected during your endoscopy exams that  are left over after the 
analyses described in the first part of this consent form are c omplete will be stored for 
research. 
• Your specimens and some related information will be stored in t he Biobank at the Mayo 
Clinic along with specimens from other people who choose to tak e part.  
• The specimens will be kept stored at the Mayo Clinic until the end of the study, when they 
may be transferred to the Nat ional Institutes of Health.  
• Qualified researchers can submit a  request to use the materials  stored in the Biobank. A 
research committee will review each request. There will also be  an ethics review to ensure 
that the request is necessary and proper. Researchers will not be given your name or any 
other information that could directly identify you.  
• Neither you nor your doctor will be notified if/when research is conducted using your 
specimens.  
• Some of your genetic and health information may be placed in th e central databases that 
may be public, along with information from many other people. I nformation that could 
directly identify you will not be included.  
 
  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
68 
 WHAT ARE THE POSSIBLE RISKS?  
  
• The most common risks related to drawing blood from your arm ar e brief pain and possibly 
a bruise.  
• There are no known risks associated with collection of urine. 
• The most common risks related to the biopsy collection are blee ding and nausea, or other 
symptoms, as the drugs used to m ake you more comfortable during the procedure wear off. 
There is a small risk of a hole in your throat or stomach. 
• There is a risk that someone could get access to the personal i nformation in your medical 
records or other information we have stored about you.  
• There is a risk that someone could trace the information in a c entral database back to you. 
Even without your name or other identifiers, your genetic infor mation is unique to you. The 
researchers believe the chance that someone will identify you i s very small, but the risk may 
change in the future as people co me up with new ways of tracing  information.  
• A new Federal law, called the Genetic Information Nondiscrimina tion Act (GINA), generally 
makes it illegal for health insurance companies, group health p lans, and most employers to 
discriminate against you based on your genetic information. Thi s law generally will protect 
you in the following ways:        
o Health insurance companies and gr oup health plans may not reque st your genetic 
information that we get from this research.  
o Health insurance companies and gr oup health plans may not use y our genetic 
information when making decisions regarding your eligibility or  premiums.        
 
Employers with 15 or more emplo yees may not use your genetic in formation that we get from 
this research when making a decision to hire, promote, or fire you or when setting the terms of 
your employment. All health insur ance companies and group healt h plans must follow this law 
by May 21, 2010. All employers w ith 15 or more employees must f ollow this law as of 
November 21, 2009.  
 
Be aware that this new Federal l aw does not protect you against  genetic discrimination by 
companies that sell life insurance, disability insurance, or lo ng-term care insurance. There are 
laws against the misuse of genetic information, but they may no t give full protection. New 
health information about inherite d traits that might affect you or your blood relatives could be 
found during a study. The research ers believe the chance these things will happen is very small, 
but cannot promise that they will not occur. 
  
HOW WILL INFORMATION ABOUT ME BE KEPT PRIVATE?  
 
Your privacy is very important to the researchers and they will  make every effort to protect it. 
Here are just a few of the steps they will take: 
• When your specimen is sent to th e researchers, no information i dentifying you (such as 
your name or social security number) will be sent. Specimens will be identified by a unique 
study code only.  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
69 
 • The list that links the unique code to your name will be kept s eparate from your specimen 
and health information. Any Biob ank and National Cancer Institu te staff with access to the 
list must sign an agreement to keep your identity confidential.  
• Researchers to whom the National  Cancer Institute sends your sp ecimen and information 
will not know who you are. They must also sign an agreement that they will not try to find 
out who you are. 
• Information that identifies you  will not be given to anyone, un less required by law. 
• If research results are published,  your name and other personal  information will not be 
used. 
 
WHAT ARE THE POSSIBLE BENEFITS?  
 
You will not benefit from taking part. The researchers, using the specimens from you and 
others, might make discoveries that could help people in the fu ture. 
 
ARE THERE ANY COSTS OR PAYMENTS?  
 
There are no costs to you or your insurance. You will not be pa id for taking part; however, you 
may receive some funds to defray some of the cost of participat ing ( e.g., parking, child care). If 
any of the research leads to new tests, drugs, or other commerc ial products, you will not share 
in any profits. 
 
WHAT IF I CHANGE MY MIND?  
 
If you decide you no longer want  your specimens to be used, you  can call the study doctor,  
<name>,  at <telephone number> who will let the researchers know. Then, any specimen that 
remains in the bank will no longe r be used. Specimens or relate d information that have already 
been given to or used by researchers will not be returned. 
 
WHAT IF I HAVE MORE QUESTIONS?  
 
If you have questions about the use of your specimens for resea rch, contact the study doctor,  
<name>,  at <telephone number>.  
 Please circle your answer to show  whether or not you would like to take part in each option: 
 
SPECIMENS AND RESULTS FOR THE LABORATORY STUDIES:   
 
I agree that my study doctors, or  their representative, may con tact me or my physician to see if 
I wish to learn about results from this study. 
  Y E S   N O  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
70 
  
 
SPECIMENS AND INFORMATION FOR FUTURE RESEARCH STUDIES:   
My blood, urine, and/or tissue specimens and related information may be kept in a Biobank for 
use in future to learn about, prevent, treat, or cure cancer an d other health problems. 
 
 Y E S   N O   
 The information from my tobacco and alcohol use questionnaires may be used in future health 
research. 
  Y E S   N O  
  My blood, urine, and/or tissue specimens and related information may be given to researchers at outside institutions 
 
YES  NO 
  I agree that my study doctors, or  their representative, may con tact me or my physician to see if 
I wish to participate in oth er research in the future. 
 
 Y E S   N O  
 
This is the end of the section about optional studies. 
 
 
  
 
     
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
71 
 My Signature Agreeing to Take Part in the Main Study  
I have read this consent form or  had it read to me. I have disc ussed it with the study doctor and 
my questions have been answere d. I will be given a signed copy of this form. I agree to take 
part in the main study and any additional studies where I circl ed “yes.”  
 
Participant’s signature ____________________ ____________ 
 Date of signature___________ ______________ ____________ 
  Signature of person(s) conducting the informed consent discussi on ___________ ___________ 
 Date of signature________ _______________ __________  
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
72 
 Study Calendar 
Time Point/Visit Tests and Procedures 
Screening • Sign informed consent document  
• Physical exam with review of vital signs (pulse, blood pressure , height, 
weight, temperature)  
• Review of existing symptoms and medications you are taking  
• Alcohol and Tobacco Use Assessment 
• Review of your medical history  
• Blood and urine tests  
• Optional blood and urine collection for research  
• Pregnancy test, if applicable  
EGD • Esophagogastroduodenoscopy (EGD) and a lower gastrointestinal ( GI) 
exam with biopsies  
Registration • Receive instructions for completing diaries and taking medicati on 
• Receive 3-month supply of study drug 
Day 1 • Starting on Day 1, take study dru g with water once a week, at a bout 
the same date and time, at least  one hour before or two hours a fter 
eating any food. 
Month 1 • Physical exam with review of vital signs (pulse, blood pressure , height, 
weight, temperature)  
• Review of side effects and sympto ms you are experiencing and an y 
medications you are taking  
• Blood and urine tests  
Months 2, 4, 5 • Phone call to see how you are doin g, ask about side effects, an d ask 
about any medications you are taking 
Month 3 • Physical exam with review of vital signs (pulse, blood pressure , height, 
weight, temperature)  
• Review of side effects and sympto ms you are experiencing and an y 
medications you are taking  
• Blood and urine tests  
• Optional blood and urine collection for research  
• Pregnancy test, if applicable  
• Collect your diaries and any unused study agent  
• Receive 3-month supply of st udy agent and new diaries  
Month 6  
(or early study 
termination) • Physical exam with review of vital signs (pulse, blood pressure , height, 
weight, temperature)  
• Review of side effects and sympto ms you are experiencing and an y 
medications you are taking  
• Blood and urine tests  
• Optional blood and urine collection for research  
• Pregnancy test, if applicable  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
73 
 • Collect your diaries and any unused study agent  
• Follow up assessment of your alcohol and tobacco use  
• Esophagogastroduodenoscopy (EGD) and possibly a lower 
gastrointestinal (GI) exam with biopsies 
• Questionnaire (Was It Worth It), which will take about 5 minute s 
Month 7 • Phone call or clinical visit to see how you are doing, ask abou t side 
effects, and ask about any medications you are taking. 
• If any of the blood test results at Month 6 were abnormal, they  will be 
repeated. 
 
  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
74 
 APPENDIX A 
Performance Status Criteria 
 
ECOG Performance Status Scale 
 
Grade Descriptions 
0 Normal activity. Fully activ e, able to carry on all pre-
disease performance without restriction. 
1 Symptoms, but ambulatory. Restricted in physically 
strenuous activity, but ambulatory and able to carry 
out work of a light o r sedentary nature ( e.g., light 
housework, office work). 
2 In bed <50% of the time. Ambulatory and capable of 
all self-care, but unabl e to carry out any work 
activities. Up and about more than 50% of waking hours. 
3 In bed >50% of the time. Capable of only limited self-
care, confined to bed or chair more than 50% of waking hours. 
4 100% bedridden. Completely disabled. Cannot carry 
on any self-care. Totally confined to bed or chair. 
5 Dead. 
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
75 
  
APPENDIX B 
Medication and Symptom Diary 
 
Participant ID ______ __________________ ____ Study physician ___ ___________ ________ 
 
Instructions:  This is a checklis t for you to use to record taking your study drug. 
Please remember that the study drug is to be taken without food . Do not eat for 2 hours before 
you take the medication or 1 hou r after you take the medication .  One suggestion would be to 
take the medication when you first get up in the morning, and t hen wait at least 1 hour before 
you have breakfast.  On the back  of this form, please note any side effects or symptoms you 
experience and any new medications (prescription, over-the-coun ter, or supplements).  
 
Week Date drug 
was taken Time drug was 
taken Fasting? 
Yes/No Time and date of last meal 
Example: 
 Week 1  11/21/2018 6:15 a.m. Yes 11/20/2018 6:30 p.m. 
 Week 1   Am 
 Pm   
 Week 2   Am 
 Pm   
 Week 3   Am 
 Pm   
 Week 4   Am 
 Pm   
 Week 5   Am 
 Pm   
 Week 6   Am 
 Pm   
 Week 7   Am 
 Pm   
 Week 8   Am 
 Pm   
 Week 9   Am 
 Pm   
 Week 10   Am 
 Pm   
 Week 11   Am 
 Pm   
 Week 12   Am 
 Pm   
 Week 13   Am 
 Pm   
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
76 
  Week 14   Am 
 Pm   
 Week 15   Am 
 Pm   
 Week 16   Am 
 Pm   
 Week 17   Am 
 Pm   
 Week 18   Am 
 Pm   
 Week 19   Am 
 Pm   
 Week 20   Am 
 Pm   
 Week 21   Am 
 Pm   
 Week 22   Am 
 Pm   
 Week 23   Am 
 Pm   
 Week 24   Am 
 Pm   
 Week 25   Am 
 Pm   
 Week 26   Am 
 Pm   
 
Remember:  There are a few foods, medications, and activities that may hav e an impact on the 
effectiveness of the study drug. Please: 
• If you use medications for acid reflux or heartburn symptoms, c heck with your study 
doctor to make sure you’re usin g the correct medication.  Do no t take any reflux or 
heartburn medication on the day before or the day of taking you r study drug, erlotinib. 
• Avoid grapefruit-containing pro ducts such as grapefruits, grape fruit juice, and any sodas 
that contain grapefruit juice (Fresca® and Squirt®). 
• You must not smoke or use any tobacco products. Urine tests wil l be done to monitor 
the amount of tobacco and sm oke you are exposed to. 
• Be sure to inform the study team of any new medications, including over-the-counter 
medications, prescription drug s, and dietary supplements. 
• Do not take more than 81 mg (1 baby aspirin) daily or 650 mg (2  adult tablets) weekly of 
aspirin or other NSAIDS.  
  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
77 
 Side Effects and Symptoms:  Please list any side effects or sym ptoms you experience, 
including the dates they started and the dates they stopped. Pl ease list any other medications 
you took, including starting and stopping dates.   If you experience a severe rash or shortness-
of-breath, contact your study doctor right away. 
 
  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
78 
  
APPENDIX C 
Was It Worth It (WIWI) Questionnaire 
 
Visit type (Time point): ______________ ___________ 
 
             --------------------- ---------------- -----------------------------  
Participating in a clinical trial  / research study is a persona l choice and an individual 
experience.  We would like to ge t your feedback on your experie nce in this research study.  
Please respond to the followi ng questions as indicated. 
 
Directions :  Please answer each question by  circling Y (for yes), N (for no), or U (for uncertain). 
 
 Was it worthwhile for you to participate in this research study ?         Y    N U 
  If you had to do it over, would you participate in this research study again?     Y    N U   Would you recommend participating in this research study to oth ers?       Y    N U 
  Directions :  Circle one response 
  Overall, did your quality of life change by participating in th is research study? 
   It improved                It sta yed the same  It got worse  
  Overall, how was your experience of participating in this resea rch study?  
   Better than I expected The same  as I expected Worse than I exp ected 
  
If there was one thing  that could have been done to improve your experience in this r esearch 
study, what would it be? 
 
 
 
 
Would you like to talk to someone about your concerns (circle o ne response)?     Yes   No 
 
_______________________________________   ___________________________________________ 
Signature                                                               Date 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
79 
 Appendix D. Alcohol Assessment: Baseline  
  
Instructions:  For the following questions about drinking alcoh olic beverages, a drink means a 12 oz. beer, a 5 oz. glass of w ine, 
or one and a half ounces of liquor. 
1. In your entire life, have you had at least 12 drinks of any kin d of alcoholic beverage? (check one)  
 Yes 
 No (End) 
 Choose not to answer (End) 
 Don’t know/Not sure 
(If No or Choose not to answer) , stop assessment 
 
2. In the past 12 months, on average, how often did you drink any type of alcoholic beverage?  (Enter the number of days you 
drank based on the timeframe chec ked below.  Enter 0 if you nev er drank and skip to Question 6.)  _______  
(If more than 0, check one)  
 Week  
 Month 
 Year 
 Choose not to answer 
 Don’t know/Not sure 
 
3. In the past 12 months, on those days that you drank alcoholic b everages, on average, how many drinks did you have per 
day?  (Enter the average number of drinks per day)_______ (If no answer, check one)  
 Choose not to answer 
 Don’t know/Not sure 
 
4. In the past 12 months, on how many days did you have 5 or more drinks of any alcoholic beverage?   
(Enter the number of days you had 5 or more drinks, or enter 0 if none.)________  
(If no answer, check one)  
 Choose not to answer 
 Don’t know/Not sure 
 
5. Was there ever a time or times in your life when you drank 5 or  more drinks of any kind of alcoholic beverage almost every 
day?  
       (check one) 
 Yes 
 No  
 Choose not to answer 
 Don’t know/Not sure 
 
6. If you do not currently drink alc oholic beverages, but did in t he past, how long has it been sin ce you last drank regularly?  
       (check one) 
 Within the past month (0 to 1 month ago) 
 Between 1 and 3 months (1 to 3 months ago) 
 Between 3 and 6 months (3 to 6 months ago) 
 Between 6 and 12 months (6 to 12 months ago) 
 Between 1 and 5 years (1 to 5 years ago) 
 Between 5 and 15 years (5 to 15 years ago) 
 More than 15 years ago  
 Don’t know/Not sure 
 Never drank regularly 
 Choose not to answer 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
80 
 Alcohol Assessment: Baseline (continued)  
 
 
7. At the heaviest point, either now or in the past, on the days w hen you drank, about how many drinks did you drink a day 
on the average?  (Enter the number of drinks a day)________  
       (If no answer, check one)   
 Choose not to answer 
 Don’t know/Not sure 
 
8. How many years have you been drinking (or did drink) regularly?     ______ years  
(If no answer, check one)  
 Choose not to answer 
 Don’t know/Not sure  
 9. At what age did you begin drinki ng regularly?   ______ years of  age  
(If no answer, check one)  
 Choose not to answer 
 Don’t know/Not sure  
 
10. What type(s) of alcohol do you drink?   
 
Wine   (check one) Yes     No     Choose not to answer 
Liquor   (check one) Yes     No     Choose not to answer 
Beer   (check one) Yes     No     Choose not to answer 
Wine cooler   (check one) Yes     No     Choose not to answer 
 
 
 
 
 
  
____________________________   ___________________________ 
Investigator Signature   Date  
 
 
 
 
 
 
 
 
 
 
  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
81 
 Appendix D. Alcohol Assessment: Follow-Up 
 
 
 Instructions:  For the following questions about drinking alcoho lic beverages, a drink means a 12 oz. beer, a 5 oz. glass of wi ne, 
or one and a half ounces of liquor. 
  1. During the past 30 days, did you drink any alcoholic beverag es?  (check one)  
 Yes 
 No (End) 
 Choose not to answer (End) 
 Don’t know/Not sure  
    (If No or Choose not to answer, stop assessment) 
 2. During the past 30 days, how many days per week or per month  did you drink any alcoholic beverages, on the average?  
(Enter number of days you drank based on the timeframe checked below.  Enter 0 if you did not drink.) ______ 
(If more than 0) , specify (check one)  
 Week  
 Month 
 Choose not to answer 
 Don’t know/Not sure 
 3. On the days when you drank, on average, about how many drink s did you have?    
(Enter the average number of drinks you had per day.) _______ 
(If no answer, check one)  
 Choose not to answer 
 Don’t know/Not sure 
 
4. In the past 30 days, on how many days did you have 5 or more  drinks per day?   _____________ 
 (Enter the number of days you had 5 or more drinks, or enter 0  if none)  
(If no answer, check one)  
  None 
  Choose not to answer  
  Do not know/Not sure 
 
 
 
 
____________________________   ___________________________ 
Investigator Signature   Date  
 
 
 
 
 
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
82 
 Appendix D. Tobacco Assessment: Baseline 
 
Section A. Basic Cigarette Use Information 
1. Have you smoked at least 100 cigarettes (5 packs = 100 cigar ettes) in your entire life? 
Yes  
 Choose not to answer → Skip to Section B   
 No → Skip to Section B  
 Don’t know/Not sure → Skip to Section B  
 
2. How old were you when you first smoked a cigarette (even one or two puffs) ?    _______ Years old  
(If no answer, check one)  
  Choose not to answer       Don’t know/Not sure 
 
3. How old were you when you fir st began smoking cigarettes reg ularly?   _______ Years old  
   (If no answer, check one)  
     Refused        Don’t know/Not sure     Check here if you have never smoked cigarettes regularly. 
 
4. How many total years have you smoked (or did you smoke) ciga rettes? Do not count any time you may have stayed off 
cigarettes.       
  (If you smoked less than one year, write “1.”)  ______ Years  
 Choose not to answer       Don’t know/Not sure 
 
5. On  average when you have smoked, about how many cigarettes do you (or did you) smoke a day?  (A pack usually has 20 
cigarettes in it).   _____ Number of cigarettes per day  
(If no answer, check one)  
 Choose not to answer       Don’t know/Not sure 
 
6. Do you NOW smoke cigarettes? (check one)  
 Everyday 
 Some days 
 Choose not to answer → Skip to question 8  
 Not at all → Skip to question 8  
 
7.  How soon after you wake up do  you smoke your first cigarett e? (check one) 
  Within 30 minutes              After 30 minutes       Choose not to answer 
 
8. How long has it been since you  last smoked a cigarette (even  one or two puffs)? First check which one of the following choices 
applies to you. Then, if applicab le, write a number on the line  for how many days, weeks, month s, or years it has been since y our 
last cigarette.  
I smoked a cigarette today (at least one puff)    (check one) Yes     No 
1-7 days   (check one)    Yes     No 
(If yes) , Number of days since last cigarette ________ 
Less than 1 month (check one)    Yes     No 
(If yes) , Number of weeks since last cigarette _________ 
Less than 1 year (check one)    Yes     No 
(If yes) , Number of months since last cigarette __________ 
More than 1 year (check one)    Yes     No 
(If yes) , Number of years since last cigarette ___________ 
Don’t know/Don’t remember   (check one)    Yes     No 
Choose not to answer  
 
 
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
83 
 Tobacco Assessment: Baseline (continued)  
Section B. Use of Other Forms of Tobacco 
 
9.  Have you ever used other form s of tobacco, not including ci garettes? (check one)  
 Yes     Choose not to answer 
 No → Skip to Section C  
 
10.  How often do you/did you use other forms of tobacco?  
Every day    (check one)      Yes     No       (If yes) , Number of times per day ________ 
Some days    (check one)    Yes     No     (If yes) , Number of days _______  
(If yes) , Per (select one)       Week        Month    Year 
 
11. Which of the following produc ts have you ever used regularly?  (Mark yes, no., or choose not to answer for all choices) 
Cigarettes  (check one)  Yes     No     Choose not to answer  
Traditional cigars, cigarillos or filtered cigars  (check one)  Yes     No     Choose not to answer  
Hookah  (check one)  Yes     No     Choose not to answer  
Bidis  (check one)  Yes     No     Choose not to answer  
Snus  (check one)  Yes     No     Choose not to answer  
E-cigarettes or other electronic nicotine delivery system  (check one)  Yes     No     Choose not to answer  
Pipes  (check one)  Yes     No     Choose not to answer  
Waterpipe (check one)  Yes     No     Choose not to answer  
Clove cigarettes or kreteks  (check one)  Yes     No     Choose not to answer  
Smokeless tobacco (like dip, chew, or snuff)  (check one)  Yes     No     Choose not to answer  
Paan with tobacco, gutka, zarda, khaini  (check one)  Yes     No     Choose not to answer  
Other, please specify: _________________________  
 
12. If you do not currently use other forms of tobacco, but did in the past, how long has it been since you last used other fo rms 
of tobacco regularly? (check one)  
 Within the past month (0 to 1 month ago)  Between 1 and 5 years (1 to 5 years ago) 
 Between 1 and 3 months (1 to 3 months ago)  Between 5 and 15 years (5 to 15 years ago) 
 Between 3 and 6 months (3 to 6 months ago)  More than 15 years ago 
 Between 6 and 12 months (6 to 12 months ago)  Don’t know/Not sure 
 Never used other forms of tobacco regularly      Choose not to answer 
 Section C. Second-Hand Smoke Exposure 
 
13. Are you currently living with a smoker?  (check one)  
Yes       No        Choose not to answer 
  
14. In the past 30 days, have you lived in a place where other people smoked cigarettes indoors?  (check one)  
Yes       No        Choose not to answer 
 
15. In the past 30 days, have you  worked in a place where other  people smoked cigarettes indoors? (check one)  
Yes       No        Choose not to answer 
 
16. Thinking of all your childh ood and adult years, have you ev er lived in a place where other people smoked cigarettes 
indoors? (check one)  
Yes → In total, for about how many years? _______ If less than 1, write “1.”   
No        
 Choose not to answer 
 
17. Thinking of all the years you have worked,  have you ever worked in a place where other people smoked cigarettes indoors?    
(check one)  
Yes → In total, for about how many years? _______ If less than 1, write “1.”   
No        
            Choose not to answer              ____________________________   ___________________________ 
                                                            Investigator Signature   Date  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
84 
 Appendix D. Tobacco Assessment: Follow-Up  
 
1. Do you NOW smoke cigarettes? (check one)  
 Everyday 
 Some days 
 Choose not to answer→ Skip to Question 4.  
 Not at all → Skip to Question 4. 
 
2. On average, when you smoked, about how many cigarettes do you (or did you) smoke a day? (A pack usually has 20 
cigarettes in it) .    
_____ Number of cigarettes per day (If no answer, check one)  
Choose not to answer      Don’t know/Not sure 
 3. How long has it been since you  last smoked a cigarette (even  one or two puffs)?   First check which one of the following 
choices applies to you. Then, if applicable, write a number on the line for how many days, weeks, months, or years it has been  
since your last cigarette.  
I smoked a cigarette today (at least one puff)   (check one)    
Yes     No 
1-7 days    (check one)    Yes     No 
 ( I f  y e s ) ,  Number of days since last cigarette _____ 
Less than 1 month   (check one)    Yes     No 
 ( I f  y e s ) ,  Number of weeks since last cigarette _____ 
Less than 1 year   (check one)    Yes     No 
 ( I f  y e s ) ,  Number of months since last cigarette _____ 
More than 1 year   (check one)    Yes     No 
 ( I f  y e s ) ,  Number of years since last cigarette _____ 
Don’t know/Don’t remember   (check one)    Yes     No 
Choose not to answer  
 4. Since your last visit,  have you used other forms of tobacco, no t including cigarettes?  (check one)  
 Yes 
 Choose not to answer (End) 
  No ( End)        (If no) , stop assessment  
 
5. How often do you/did you use other forms of tobacco?  
Every day    (check one)    Yes     No      (If yes),  Number of times per day ________ 
Some days   (check one)    Yes     No     (If yes),  Number of days ________  
                                                                (If yes) , per (select one)     Week    Month    Year 
     Choose not to answer 
 
6.   Since your last visit, which of the following products hav e you used?  (Mark yes or no fo r all choices) 
Cigarettes  (check one)  Yes     No     Choose not to answer 
Traditional cigars, cigarillos or filtered cigars  (check one)  Yes     No     Choose not to answer  
Hookah  (check one)  Yes     No     Choose not to answer  
Bidis  (check one)  Yes     No     Choose not to answer  
Snus  (check one)  Yes     No     Choose not to answer  
E-cigarettes or other electronic nicotine delivery system  (check one)  Yes     No     Choose not to answer  
Pipes  (check one)  Yes     No     Choose not to answer  
Waterpipe (check one)  Yes     No     Choose not to answer  
Clove cigarettes or kreteks  (check one)  Yes     No     Choose not to answer  
Smokeless tobacco (like dip, chew, or snuff)  (check one)  Yes     No     Choose not to answer  
Paan with tobacco, gutka, zarda, khaini (check one)  Yes     No     Choose not to answer  
Other, please specify: _________________________  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
85 
 Tobacco Assessment: Follow-Up (continued)  
 
7. If you do not currently use other forms of tobacco, but did in the past, how long has it been since you last used other for ms 
of tobacco regularly? (check one)  
 Within the past month (0 to 1 month ago) 
 Between 1 and 3 months (1 to 3 months ago) 
 Between 3 and 6 months (3 to 6 months ago) 
 Between 6 and 12 months (6 to 12 months ago) 
 Between 1 and 5 years (1 to 5 years ago) 
 Between 5 and 15 years (5 to 15 years ago) 
 More than 15 years ago 
 Don’t know/Not sure 
 Choose not to answer 
 Never used other forms of tobacco regularly  
 The following instructions pertain to questions 8 -10.  During each of the following time frames, please indicate whether you 
smoked cigarettes every day, some days, or not at all. 
 
8.  During study treatment (check one)  
 Smoked every day 
 Smoked some days 
 Did not smoke at all 
 Don’t know/not sure 
 Choose not to answer 
 Not applicable  
 9.  After the end of study treatment (check one)   
 Smoked every day 
 Smoked some days 
 Did not smoke at all 
 Don’t know/not sure 
 Choose not to answer 
 Not applicable (I have not completed the study treatment) 
   
10.  Since your last v isit to this clinic (check one)   
 Smoked every day 
 Smoked some days 
 Did not smoke at all 
 Don’t know/not sure 
 Choose not to answer 
 Not applicable (This is my f irst visit to this clinic) 
 
 
____________________________   ___________________________ 
Investigator Signature   Date  
  
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
86 
 Appendix E. Alcohol and Tobacco Cessation Resources 
National and local resources to help with alcohol abuse and alc oholism 
NIAAA’s online guide Treatment for Alcohol Problems: Finding and Getting Help  is written for 
individuals, and their family and friends, who are looking for options to address alcohol 
problems. It is intended as a r esource to understand what treatment choices are available and 
what to consider when selecting among them. 
https://pubs.niaaa.nih.gov/publicat ions/treatment/treatment.htm  
Other resources: 
National Institute on Alco hol Abuse and Alcoholism www.niaaa.nih.gov  
301–443–3860  
National Institute on Drug Abuse www.nida.nih.gov  
301–443–1124  National Clearinghouse for Al cohol and Drug Information www.samhsa.gov  
1–800–729–6686  
Substance Abuse Treatment Facility Locator www.findtreatment.samhsa.gov  
1–800–662–HELP  
Alcoholics Anonymous (AA) www.aa.org  
212–870–3400 or check your local phone directory under “Alcohol ism”  
Moderation Management www.moderation.org  
212–871–0974  
Secular Organizations for Sobriety www.sossobriety.org  
323–666–4295  
SMART Recovery www.smartrecovery.org  
440–951–5357  
Women for Sobriety www.womenforsobriety.org  
215–536–8026  
Al-Anon Family Groups www.al-anon.alateen.org  
1–888–425–2666 for meetings  Adult Children of Alcoholics www.adultchildren.org  
310–534–1815   
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
87 
 National and local resources to  help with quitting smoking 
NCI’s Smokefree.gov  offers science-driven tools, information, and support that has  helped 
smokers quit. You will find state and national resources, free materials, and quitting advice 
from NCI. 
Smokefree.gov was established by the Tobacco Control Research Branch  of NCI, a component 
of the National Institutes of Health, in collaboration with the  Centers for Disease Control and 
Prevention and other organizations. 
Publications available from the S mokefree.gov Web site include the following: 
• Clearing the Air: Quit Smoking Today  for smokers interested in quitting. 
• Clear Horizons for smokers over age 50. 
• Forever Free™   for smokers who have recently quit. 
• Forever Free for Baby and Me™ , in English  and Spanish , for pregnant smokers who have 
recently quit. 
• Pathways to Freedom: Winning the Fight Against Tobacco  for African American smokers. 
NCI’s Smoking Quitline at 1–877–44U–QUIT ( 1–877–448–7848)  offers a wide range of services, 
including individualized counseling, printed information, refer rals to other resources, and 
recorded messages. Smoking cessa tion counselors are available to answer smoking-related 
questions in English or Spanish, Monday through Friday, 8:00 a. m. to 8:00 p.m., Eastern Time. 
Smoking cessation counselors a re also available through LiveHelp , an online instant messaging 
service. LiveHelp is available M onday through Friday, 8:00 a.m.  to 11:00 p.m., Eastern Time. 
Your state has a toll-free telephone quitline. Call 1–800–QUIT–NOW ( 1–800–784–8669)  to get 
one-on-one help with quitting, support and coping strategies, and referrals to resources and 
local cessation programs. The t oll-free number routes callers to state-run quitlines, which 
provide free cessation assistance  and resource information to a ll tobacco users in the United 
States. This initiative was created by the Department of Health and Human Services . For more 
information about quitlines, speak to an expert  on the Smokefree.gov Web site. 
 
   
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
88 
 Appendix F.  Diary of Medications Used for Acid Reflux Symptoms  
 
Participant ID ______ __________________ ____ Study physician ___ ___________ ________ 
 
Instructions:  Use this diary to record any medications used fo r symptoms related to acid reflux 
or upset stomach.  Use the back of this page for any other note s or comments.   
 REMEMBER :  These medications may interfe re with the effectiveness of erlotinib.  You are 
asked to avoid these medication s on the day before and the day you actually take your weekly 
erlotinib.  Please let your study  team know if you have any que stions or problems. 
 
Date/Time Name of antacid taken Dose Name of H2 receptor 
agonist Dose 
Example: 1/11/2018 
8:00 p.m. Tums – Extra strength 2 tablets = 1500 mg   
Example:  1/19/2018 8:00 p.m.   ranitidine 150 mg 
     
     
     
     
     
     
     
     
     
MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
89 
 Date/Time  Name of antacid taken  Dose  Name of H2 receptor 
agonist  Dose  
     
     
     
     
     
     
     
     
   
 _________________________________ ____________   _ ______________ ____ 
Participant signatur e                                                                  Date
 